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Abstract 
There is a requirement for the characterisation of the metabolism of xenobiotics in zebrafish 
larvae, due to the application of this organism to toxicity testing and ecotoxicology.  Genes 
similar to mammalian cytochrome P450 (CYP) 1A1, CYP2B6, CYP3A5 and UDP-
glucuronosyl-transferase (UGT) 1A1 were demonstrated to be expressed during normal 
embryonic development, with increased expression post hatching in Wik strain zebrafish 
larvae (72 hours post fertilisation, hpf).  Activities towards ethoxy-resorufin, 7-ethoxy-
coumarin and octyloxymethylresorufin, using an in vivo larval assay, were also detected in 
96 hpf Wik strain zebrafish larvae, indicative of oxidative and conjugative metabolism.  The 
expression of the identified genes was modulated upon exposure to Aroclor 1254, and the 
metabolic activities towards ethoxy-resorufin, 7-ethoxy-coumarin and 
octyloxymethylresorufin were observed to be inducible by exposure to in vitro inhibitors of 
CYP activities.  Wik strain zebrafish larvae (72 hpf) were also demonstrated to metabolise 
the pharmaceuticals acetaminophen and ibuprofen by oxidative and conjugative processes 
using liquid chromatography mass spectrometry and scintillation counting.  Finally, the 
organic solvents dimethyl-sulfoxide and methanol were observed to reduce the expression of 
CYP and UGT genes, and the metabolism of ethoxy-resorufin, after 24 hours exposure to 
≤0.1% volume/volume concentrations of the two solvents.  It is suggested that these 
inhibitory effects are in part due to a reduction in the expression of the aryl hydrocarbon 
receptors, which are known regulators of drug metabolism genes.  Overall the expression of 
genes and enzymatic activities similar to the mammalian drug metabolism genes have been 
demonstrated in Wik strain zebrafish larvae (96 hpf), and the first examples of the 
metabolism of pharmaceuticals by zebrafish larvae are also demonstrated.  The modulation 
of the metabolism of xenobiotics by organic solvents suggests that caution must be 
exercised when interpreting data from toxicity tests when high solvent concentrations are 
applied to zebrafish larvae.  The continued use of zebrafish larvae as a toxicity testing model 
is strengthened by the findings of this work. 
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1.0 General introduction 
There is increasing interest in the use of zebrafish (Danio rerio) larvae as a model organism 
for toxicity testing, ecotoxicology screening and disease modelling, with a particular focus on 
drug screening assays (Berghmans et al 2008, Richards et al 2008, Winter et al 2008).  The 
importance of metabolism upon the toxicity and pharmacology of chemicals is well 
documented (see below), and it is important that the extent to which such processes occur in 
zebrafish larvae is assessed if these organisms are to be used effectively for chemical 
screening.  The detection of pharmaceutical residues in the aquatic environment has also 
resulted in an interest in the fate of these chemicals in aquatic organisms such as fish (Dorne 
et al 2007).  The potential for the metabolism of xenobiotics has not been fully characterised 
in zebrafish, and with the application of zebrafish to ecotoxicology and toxicity testing, it is 
essential that these processes are understood.  This project focuses upon the 
characterisation of the potential for the metabolism of xenobiotics by zebrafish larvae, in 
relation to the application of these fish in drug screening and ecotoxicology testing.  As an 
introduction, this chapter reviews the principles of drug metabolism, summarising the 
expression of relevant genes with examples of substrates for the different enzymatic systems 
involved in the metabolism of xenobiotics, and comparisons between different mammalian 
and fish species are drawn, with a focus upon zebrafish. 
  
1.1.1 Drug metabolism 
There are several different processes that can occur to metabolise a compound, including 
oxidation, reduction and conjugation reactions.  Generally, oxidative and reductive processes 
expose functional moieties on a compound (known as phase I metabolism), which can then 
undergo conjugation (known as phase II metabolism) with sugars (e.g. glucuronic acid), a 
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peptide (glutathione), amino acids (e.g. glycine) or other moieties (e.g. sulfonate) resulting in 
a more readily excreted product (Nebbia 2001).  If an appropriate functional group is already 
present in a molecule then conjugation reactions can occur without prior phase I metabolism.  
For example, acetaminophen can be directly conjugated to both sulfate or glucuronic acid 
moieties without any prior oxidation due to the presence of a functional hydroxyl group, 
whereas benzene requires oxidative hydroxylation via an epoxide intermediate (resulting in 
the formation of a functional group) before it can undergo conjugation (see Figure 1.1, Snyder 
and Hedli 1996, Pirmohamed 2008).  Generally, the exposure of a functional group (through 
phase I metabolism) is required before subsequent conjugation reactions (phase II 
metabolism) followed by excretion, which can be mediated by drug transporter proteins such 
as P-glycoprotein, multi-drug resistance protein and organic anion transporter proteins (Xu et 
al 2005).  These transporter proteins play a critical role in the influx, efflux and distribution of 
xenobiotic and endobiotic compounds in many tissues including the brain, kidney, liver and 
intestine in humans (Xu et al 2005).  There is a variety of enzymatic systems that catalyse the 
oxidation, reduction and conjugation processes involved in drug metabolism, and these have 
been extensively characterised and reviewed for mammalian species and are discussed 
below (Hayes and Pulford 1995, Guengerich 2001, Gamage et al 2001, Guillemette 2003, 
Hayes et al 2005, Guengerich 2006, Brown et al 2008, Testa and Krämer 2008).  
 
The toxicity of xenobiotics can be modulated by metabolic processes such as oxidation and 
conjugation reactions.  Thus there is the potential for the conversion of a toxic compound into 
a non-toxic derivative and vice versa.  It is therefore clear that the metabolism of xenobiotics 
is of great importance in terms of the safety assessment of drug candidate molecules, and in 
the environmental fate of xenobiotics, and the effects of such compounds upon non-human 
species including fish and aquatic invertebrates.  The processes of xenobiotic metabolism are 
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aimed at converting a compound into a more readily excreted, and usually less toxic 
(although this is not always the case), form so that the compound can be cleared from the 
body.   
 
1.1.2 Cytochromes P450 and drug metabolism 
 
The cytochromes P450 (CYP) are a group of heme-containing (heme-thiolate) enzymes 
present in a wide variety of species, ranging from plants and animals to micro-organisms 
(Anzenbacher and Anzenbacherova 2001).  The CYP enzymes have been implicated in a 
wide variety of processes such as pigment synthesis, defence against chemical insult and the 
synthesis of steroids, prostaglandins and retinoic acid (Nebert and Dalton 2006).  There have 
been 57 CYP genes identified in humans to date, with similar genes grouped into families 
and sub-families based on amino acid sequence similarity derived from the gene sequence 
(>40% for the same family and >55% for the same sub-family, Brown et al 2008).     
 
There are a wide variety of reactions that can be catalysed by CYP enzymes, ranging from 
mono-oxidation of compounds to the dehydration, dehydrogenation, isomerisation and 
reduction of substrates (Mansuy 1998).  Mono-oxidation reactions involve the insertion of an 
oxygen atom into the carbon-hydrogen (C-H) bond resulting in the hydroxylation of the 
substrate (Mansuy 1998).  Depending on the nature of the substrate this type of reaction can 
result in oxidative de-alkylations (the insertion of oxygen at a C-H bond next to a heteroatom 
such as oxygen, nitrogen or sulfur can result in the cleavage of the heteroatom bond and de-
alkylation, Mansuy 1998).  The hydroxylation of amines (primary and secondary), carbon 
double bonds, aromatic rings and lone pairs of heteroatoms can also be catalysed by CYP 
enzymes resulting in the formation species such as epoxides, arene oxides, N-oxides and 
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Oxidative metabolism and glutathione conjugation
AcetaminophenAcetaminophen glucuronide Acetaminophen sulfate
SULTUGT
 
 
 
Benzene Epoxide 
intermediate
Phenol
Glucuronic acid conjugate
 
 
Figure 1.1:  The metabolism of acetaminophen (A) and a simplified schematic of benzene 
metabolism (B).  Acetaminophen can undergo conjugation with glucuronic acid or sulfate 
moieties without prior activation by oxidative metabolism, whereas benzene requires 
oxidation to phenol (via an epoxide intermediate) before it can undergo conjugation reactions.  
SULT (Sulfotransferases) and UGT (UDP-glucuronosyl transferases) 
 
(A) 
(B) 
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sulfoxides, depending on the substrate (Mansuy 1998).  Other oxidation reactions catalysed 
by CYP enzymes include peroxidase-like activities and dehydrogenation reactions (formation 
of carbon double bonds from CH-CH in substrates such as testosterone, Mansuy 1998).   
 
A generalised reaction mechanism for CYP-catalysed oxidation reactions is shown in Figure 
1.2, adapted from Guengerich 2001.  Briefly, this mechanism involves the binding of the 
substrate (1), followed by the reduction of the iron centre (with the electron donated by 
NADPH-P450-reductase, 2) and binding of molecular oxygen (3).  The complex formed by 
the binding of oxygen is very unstable and can result in the production of superoxide anions 
(Guengerich 2001).  A second electron, donated either by cytochrome B5 or NADPH-P450-
reductase (4), further reduces the iron-oxygen complex, and this is followed by the addition of 
a proton and the cleavage of the oxygen-oxygen (O-O) bond, releasing water (5 and 6 
respectively).  Finally, the resulting electron-deficient complex abstracts either a hydrogen or 
an electron from the substrate (7), and the resulting intermediate collapses, producing the 
oxidised substrate and regenerates the iron centre (8 and 9).   
 
There are also several non-oxidation reactions catalysed by CYP enzymes.  Prostaglandin 
synthesis involves the isomerisation of prostaglandin H2 (PGH2) to form prostacyclin (PGI2) or 
thromboxane, reactions that are catalysed by two CYP enzymes (prostacyclin synthase and 
thromboxane synthase, Mansuy 1998). The reduction of polyhalogenated substrates, 
nitoraromatic compounds, tertiary amines and arene oxides has been well reported (Mansuy 
1998).  These reduction reactions occur under anaerobic conditions, as the P450 is required 
to be in a reduced state in order to catalyse these reactions (Mansuy 1998).    
 
 
  
7 
 
 
 
 
 
 
Figure 1.2:  The proposed catalytic cycle of cytochromes P450 for oxidation reactions 
(Adapted from Guengerich 2001).  The enzyme substrate is designated RH and the product 
is designated ROH.  The iron atom in the heme of the cytochrome P450 is designated Fe. 
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The metabolism of the majority of xenobiotics and foreign compounds is catalysed by CYP 
family 1, 2 and 3 isoforms.  Although there is considerable overlap of specificity towards 
substrates between different families and individual isoforms, each family tends to have a (if 
broad) specificity towards substrates of certain physiochemical properties (Pelkonen et al 
2008).  The potential for a substrate to be metabolised by multiple CYP isoforms is of great 
mechanistic importance when considering the potential for drug-drug interactions (where 
multiple compounds requiring metabolism by the same enzyme isoform compete for 
enzymatic metabolism, or where one compound modulates the activity/expression of an 
isoform that metabolises another compound), as a compound metabolised by a single 
isoform will be considerably more susceptible to these kinds of interactions than a compound 
metabolised by multiple enzymes (Pelkonen et al 2008).   
 
The CYP1 family are responsible for the metabolism of polyaromatic hydrocarbons (PAH), 
aromatic amines and some pharmaceuticals such as acetaminophen and caffeine (Brown et 
al 2008). There are currently 3 identified members of CYP1 enzymes, CYP1A1, CYP1A2 and 
CYP1B1.  The CYP1A1 isoform has been demonstrated to be expressed in a variety of 
different tissues but frequently is only detected after induction of this gene by ligands of the 
aryl hydrocarbon receptor (AhR), whereas CYP1A2 is expressed mainly in the liver of 
humans at high levels and has been shown to be inducible by AhR ligands (Omiescinski et al 
1999).  It has been reported that CYP1B1 is expressed in a variety of extrahepatic human 
tissues, such as kidney, liver, brain, breast and lung, albeit at a very low level (Murray et al 
2001).  Compounds such as PAH and polyhalogenated aromatic hydrocarbons (PHAH, such 
as polychlorinated biphenyls and dioxin-like compounds) are generally metabolised by 
CYP1A1 and CYP1B1, whereas the metabolism of aromatic amines is catalysed largely by 
CYP1A2 (Nebert and Dalton 2006).  The metabolism of these compounds can result in the 
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formation of reactive epoxides or quinone derivatives, and such metabolites have been 
implicated in carcinogenesis (Shimada and Guengerich 2006).  The N-hydroxylation of 2-
amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP), a reaction catalysed by CYP1A2, 
followed by sulfation or acetylation has been demonstrated to result in a carcinogenic species 
that can modify guanine bases in DNA (Malfatti et al 2005, Metry et al 2007).  Indeed, the 
importance of CYP1A2 in the bioactivation of PhIP has been demonstrated in vivo using 
CYP1A2 null mice (Kim and Guengerich 2005).  The CYP1 family enzyme CYP1B1 has also 
been reported to have a role in the bioactivation of heterocyclic arylamines using recombinant 
CYP1B1 expressed in Escherichia.coli (E. coli, Shimada et al 2001).  The CYP1A2 and 
CYP1B1 enzymes have been reported to metabolise oestrogen to its 2- and 4-hydroxy-
derivatives, as well as being involved in the metabolism of xenobiotics, unlike CYP1A1 
(Hasler et al 1999).  For example, the anti-androgenic drug flutamide undergoes 
hydroxylation, catalyzed by CYP1A2, and both CYP1A2 and CYP1B1 have been 
demonstrated, using recombinant enzymes, to catalyze the 4-hydroxylation of tamoxifen 
(CYP1A2) and the isomerisation of trans-4-hydroxy-tamoxifen to its cis-derivative (CYP1B1, 
Crewe et al 2002).  Other CYP1B1 substrates identified, using recombinant human CYP1B1, 
include 7-ethoxy-resorufin, bufuralol, theophylline and 7-ethoxy-coumarin (Shimada et al 
1997).  The 3-N-demethylation of caffeine to paraxanthine is considered as a marker activity 
for CYP1A2 in humans, whereas the 8-C-hydroxylation of caffeine identified as a CYP1A2 
marker in rats (Kot and Daniel 2008).  The 4-hydroxylation of oestrogen is used as a specific 
indicator of CYP1B1 activity (Shimada et al 1997).   
 
The CYP2 family comprises of several important drug metabolising enzymes including 
CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2D6 (Guengerich 2006).  The CYP2 family 
genes are expressed in a variety of human tissues including lung, kidney, small intestine and 
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brain (Nishimura et al 2003).  However, the CYP2 genes are most highly expressed (based 
upon mRNA levels) in the liver, with CYP2E1 having the highest level of mRNA present in the 
liver out of all the CYP genes in humans (Nishimura et al 2003, Biéche et al 2007).  There is 
no common pattern of regulation or specificity towards substrates for members of the CYP2 
family, for example CYP2B6 metabolises non-planar compounds that are weakly basic or 
neutral whereas the CYP2C enzymes are reported to metabolise a wide range of drugs (up to 
20% of all prescribed drugs) that contain at one or more aromatic ring moieties and are 
weakly acidic in nature (Totah and Rettie 2005, Brown et al 2008).  The CYP2D6 isoform has 
been implicated in the metabolism of compounds that contain a basic nitrogen atom 
approximately 5 angstroms for sites of oxidation, and CYP2E1 substrates are small 
molecules that can be halogenated, hydrophobic or hydrophilic (Brown et al 2008).  The 
CYP2D6 enzyme is of great clinical relevance, as it can metabolise compounds from a wide 
variety of different therapeutic classes, including: analgesics, anti-arrhythmics, anti-
depressants, anti-hypertensives, anti-emetics, anti-histamines, anti-psychotics, beta-
adrenergic blocking compounds as well as anti-diabetic compounds (Zanger et al 2004).  
Thus substrates of this family of enzymes span a wide variety of pharmaceutical groups 
(examples of CYP2 substrates are given in Table 1.1). The CYP2B6 and CYP2E1 isoforms 
have also been implicated in the activation of pro-carcinogens and toxic species such as 
diethylnitrosamine, and CYP2E1 is a well-described source of reactive oxygen species due to 
poor coupling of its redox cycle (Omiecinski et al 1999, Kang et al 2007, Miller 2008, 
Pelkoven et al 2008).    
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Table 1.1: Examples of substrates metabolised by CYP2 enzyme family.   
 
These compounds are from a wide variety of different chemical and pharmacological classes 
of compounds with a broad range of different physiochemical properties.  It should be noted 
that this is not an exhaustive list of substrates for these enzymes, and that these examples 
have been selected to highlight the wide variety of therapeutic classes metabolised by the 
CYP2 enzymes. 
 
 
 
 
Isoform Example Substrates Reference 
CYP2B6 
Bupropion,  Diazepam,  Efavirenz, Ketamine,  
Lidocaine, Methadone Midazolam, Tamoxifen 
Ekins et al 2008 
CYP2C8 
Cerivastatin, Chloroquine, Diclofenac,  Ibuprofen, 
Methadone, Morphine, Rosiglitazone, Warfarin 
Tolah and Rettie 
2005 
CYP2C9 
Celecoxib, Diclofenac, Ibuprofen, Phenytonin, 
Naproxen, Tamoxifen, Tolbutamide, Warfarin 
Hersh and 
Moore 2004 
CYP2C19 
Chlopyrifos, Diazepam, Diclofenac, Fluoxetine, 
Omeprozole,  S-mephenytoin, Tolbutamide, 
Warfarin 
Wang et al 2004, 
Brown et al 2008 
CYP2D6 
Codeine, Debrisoquine, Propranolol, Nicergoline, 
Tamoxifen 
Zagner et al 
2004 
CYP2E1 
Acetaminophen, Acetone,  Ethanol, Halogenated 
anesthetics, Benzene 
Brown et al 2008 
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The CYP3 family consists of 5 isoforms, CYP3A3, CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43 in humans (McArthur et al 2003, Nelson 2009).  The CYP3 isoforms are expressed 
in a range of human tissues including the liver, lung, kidney, intestine and brain, with the 
highest expression found in the liver, particularly the CYP3A4 isoform, and CYP3A7 is mainly 
expressed in foetal tissues with minimal expression in human adult tissues (Nishimura et al 
2003).  It has been reported by Williams et al (2002), using a variety of CYP3 substrates, that 
CYP3A5 generally has an equivalent or lower metabolic capacity than CYP3A4, with 
CYP3A7 having the lowest capacity of all the isoforms.  The CYP3A5 isoform has been 
reported to only be expressed in a relatively small percentage of the Caucasian population 
(<25%), resulting in some dispute regarding the relative importance of this isoform to the 
metabolism of xenobiotics (Brown et al 2008).  The CYP3A enzymes have broad substrate 
specificities, metabolising endogenous steroids, such as testosterone progesterone and 
oestradiol, as well as a wide range of pharmaceutical compounds (de Wildt et al 1999).    
These pharmaceuticals tend to be large molecular weight compounds from a diverse range of 
therapeutic classes including, diazepam (benzodiazepine), diclofenac (non-steroidal anti-
inflammatory drug, NSAID), erythromycin (antibiotic) midazolam (benzodiazepine), nifedipine 
(anti-hypertensive) and tamoxifen (chemotherapeutic drug, de Wildt et al 1999, Brown et al 
2008).   
 
 
1.1.3 Glutathione-S-Transferases 
The Glutathione-S-Transferase (GST) enzymes are a group of broad-specificity enzymes that 
catalyse the addition of the tripeptide glutathione (glutamate-cysteine-glycine, GSH) to a 
large variety of substrates including pharmaceuticals, endogenous metabolites and oxidised 
species that contain an electrophilic centre (Hayes and Pulford 1995).  There are 3 different 
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types of GST enzymes, cytosolic, mitochondrial and microsomal (also known as membrane 
associated proteins in eicosanoid and glutathione – MAPEG, Hayes et al 2005).  All of the 
members of these families metabolise the GST marker substrate 1-chloro-2,4-dinitrobenzene 
(CDNB, Hayes et al 2005).  The GSTs are divided into the families alpha, mu, pi, sigma and 
theta, with classification based on predicted amino acid sequence identity (40% or greater for 
same family, although this is not a definitive classification and there can be some difficulty 
assigning some genes to a given family, Hayes and Pulford 1995).  The cytosolic GST 
enzymes are divided into 5 alpha family enzymes, 5 mu family, 1 pi, 1 sigma, 2 theta, 1 zeta 
and 2 kappa isoforms (Hayes et al 2005), whereas there is only single identified 
mitochondrial GST identified in humans (a kappa family enzyme, Hayes et al 2005).  Soluble 
GST proteins have been detected in a variety of human tissues, including brain, heart, 
kidney, liver, lung, pancreas and the small intestine (Sherratt et al 1997).  Different isoforms 
within and between families have different tissue patterns of expression, with (for example) 
GST theta detected in all tissues, whereas GST alpha-1 is mainly found in kidney and liver 
and testis tissues (Sherratt et al 1997).  Examples of GST substrates include 
pharmaceuticals such as acetaminophen (after oxidation by CYP2E1 and CYP3A4 to the 
reactive intermediate N-acetyl-p-benzoquinoneimine), cyclophosphamide (chemotherapeutic 
agent), chlorabucil (chemotherapeutic agent) and fosfomycin (antibiotic), as well as epoxide 
derivatives of xenobiotic compounds such as PAH and halogenated aliphatic compounds 
(Dirven et al 1994, Hayes et al 2005, Parker et al 2008, Pirmohamed 2008, Pushparajah et al 
2008).  As the electrophilic centre of GST substrates can be centred upon a carbon, nitrogen 
or sulfur atom there are a vast amount of substrates for these enzymes, and this promiscuity 
is facilitated by a hydrophobic substrate binding site that has a broad specificity for a wide 
range of compounds (Hayes and Pulford 1995).  Although the majority of GSH-conjugates 
are less toxic and more readily excreted that the parent compound there are examples of 
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GSH-conjugation resulting in the production of toxic species as a result of unstable and 
reversible conjugates, resulting in cleavage back to the un-conjugated species, or the 
production of a GSH-conjugate that is more reactive than the parent compound (Hayes and 
Pulford 1995).  Examples of compounds that undergo these processes are p-nitrophenol 
acetate, fluorodifen, benzyl, phenyl and allyl isothiocyanate and alkyldihalides (Hayes and 
Pulford 1995).  In addition to the conjugation of GSH to electrophilic substrates GST enzymes 
can also catalyse the reduction of products of oxidative stress (such as DNA and 
phospholipid hydroperoxides, Hayes and Pulford 1995).  The GST enzymes have also been 
shown to function as peroxidases and isomerases and thus are involved in phenylalanine 
degradation, testosterone and progesterone synthesis, and arachidonic acid metabolism 
(Hayes and Pulford 1995, Hayes et al 2006).  It should be noted that glutathione conjugates 
can undergo further metabolism to form mercapturic acid derivatives (Hinchman et al 1991).  
This process involves the sequential removal of the glutamate and glycine residues 
(catalysed by γ-glutamyl-transpepidase and dipeptidases respectively) to form a cysteine-S-
conjugate, which can then undergo acetylation catalysed by N-acetyl transferases (Hinchman 
et al 1991).  
 
 
1.1.4 UDP-glucuronosyl transferases 
The UDP-glucuronosyl-transferases (UGT) catalyse the addition of a glucuronic acid moiety, 
from the endogenous precursor UDP-glucuronic acid, to a wide range of different nucleophilic 
functional groups of endogenous and exogenous compounds, including hydroxyl, carboxylic 
acid, amines (primary, secondary and tertiary), sulfhydryl and ester moieties (Testa and 
Krämer 2008).  The UGT enzymes are described as low affinity but high capacity systems, 
with high molecular weight products of glucuronidation (molecular weight >450) frequently 
  
15 
 
excreted in bile (Testa and Krämer 2008).  There are 4 distinct families of UGT enzymes (1, 
2, 3 and 8) currently known in humans, with family 1 comprising 10 isoforms (UGT1A1 – 
UGT1A10), family 2 divided into subfamilies UGT2A (UGT2A1 – UGT2A3) and UGT2B 
(UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17 and UGT2B18), UGT3 
comprised of 2 isoforms (UGT3A1 and UGT3A2) and a single UGT8 enzyme (Testa and 
Krämer 2008).  The UGT enzymes are found in a wide range of different organs in humans, 
especially the liver and intestine, but also the nasal mucosa, skin, lung, brain, kidneys, 
prostate, uterus, breast and placenta (Guillemette 2003).  Due to the variety of chemical 
entities that can be conjugated by UGT isoforms, there is a wide range of environmental 
chemicals, pharmaceuticals, xenobiotics and endogenous compounds that can undergo 
conjugation to glucuronic acid, and thus UGT enzymes have been described as having broad 
and overlapping substrate specificities (Guillemette 2003).  The benzodiazepine midazolam 
has been reported to undergo N-glucuronidation (with UGT1A4 implicated as the major 
isoforms responsible for catalysing this reaction), as well as O-glucuronidation of the hydroxy-
derivatives of midazolam, and the β-blocker propanolol has been reported to undergo 
stereoselective N-glucuronidation by a variety of different UGT isoforms including UGT1A9, 
UGT2B4 and UGT2B7 (Hanioka et al 2008, Klieber et al 2008, Hyland et al 2009).  Bisphenol 
A is conjugated to glucuronic acid using human liver microsomes, and in vitro experiments 
suggest that UGT2B15 is the major isoforms responsible for this conjugation (Hanioka et al 
2008).  Caricinogens such as the nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) can undergo N-glucuronidation, resulting in the formation of non-tumorigenic 
glucuronide derivatives (Chen et al 2008).  Other examples of UGT substrates are morphine 
and acetaminophen (O-glucuronidation), malotliate (S-glucuronidation) and sulfinpyrazone 
(C-glucuronidation (Testa and Krämer 2008).  Endogenous substrates of the UGT enzymes 
include steroid hormones (e.g. testosterone, androsterone and β-oestradiol), bile acids (e.g. 
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lithocholic acid, deoxycholic acid and chenodeoxycholic acid) and billirubin (Testa and 
Krämer 2008). 
 
1.1.5  Sulfotransferases 
The conjugation of xenobiotics and endogenous compounds to sulfonate moieties, derived 
from the endogenous sulphate donor 5’-phosphoadenosine-3’-phosphosulphate (PAPS) is 
catalysed by a group of enzymes termed Sulfotransferases (SULT), and generally functions 
to yield a more readily-excreted product, although the production of electrophilic (and thus 
chemically-reactive) species have been reported (Glatt 2000, Glatt et al 2001, Gamage et al 
2005).  The conjugation of a substrate to a sulfonate moiety occurs at nucleophilic atoms, 
such as oxygen, nitrogen or sulphur, and it is due to this that the term sulfonation, rather than 
sulfation (the process of the conjugation of a sulfonate moiety to an oxygen atom), is used for 
this process.  The formation of O-sulfate derivatives of compounds such as 4-
aminoazobenzene has been reported to result in the formation of carcinogenic species (Glatt 
2000).  As with the previously discussed CYP, GST and UGT genes and enzymes, members 
of the SULT superfamily are classified into distinct families and subfamilies, based upon 
percentage identity of the predicted amino acid sequence.  There are currently 3 families of 
SULT (family 1, family 2 and family 4), and each family, broadly speaking, has different 
substrate specificities (Glatt et al 2001).  The SULT1 family isoforms are known as phenolic 
SULTs, and metabolise a broad range of substrates including xenobiotics (e.g. 
acetaminophen, 1-naphthol, 4-nitrophenol, 4-hydroxy-tamoxifen and vanillin and naproxen 
derivatives) and endogenous compounds such as neurotransmitters (e.g. dopamine), 
whereas SULT2 family members are also known as hydroxy-steroid metabolising SULTs, 
with substrates including testosterone, dehydroepiandrosterone, 17-ethinyl-oestradiol and 
various bile acids (Glatt et al 2001, Falany et al 2005).  It should be noted that the SULT2 
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isoforms can also metabolise some pharmaceuticals, for example 4-hydroxy-tamoxifen is a 
substrate for several SULT1 isoforms as well as for SULT2A1 (Falany et al 2006).  There are 
currently no identified substrates of the SULT4 family enzymes (Gamage et al 2005).  The 
SULT1A isoforms are found in a variety of different tissues, with SULT1A detected in the liver 
(high levels of SULT1A1), brain, breast, intestine (high levels of SULT1A3 detected), 
endometrium, adrenal gland, platelets and the lungs (both SULT1A1 and SULT1A3), 
whereas SULT1A2 protein has not been detected in any tissues screened despite the 
detection of corresponding mRNA (Gamage et al 2005).  Other SULT1 enzymes (SULT1B, 
SULT1C and SULT1E) have been detected in several tissues such as intestine, colon, 
stomach, kidney and thyroids and liver, and these enzymes have been implicated in thyroid 
metabolism (SULT1B1), oestrogen metabolism (SULT1E1) or have unknown physiological 
roles (Gamage et al 2005).  The SULT2 genes are localised in hormone-responsive tissues, 
in keeping with the role of these enzymes in the metabolism of hydroxy-steroids, although the 
different isoforms do have slightly different patterns of tissue expression (Gamage et al 
2005).   
 
 
1.1.6 Other xenobiotic-metabolism systems 
Although the systems described above can be thought of as the “major” pathways for the 
metabolism of xenobiotics, there are other potential metabolic pathways present, and some 
of these “minor” pathways can be, for certain substrates, a significant route of metabolism.  In 
addition to CYP-dependent oxidation of substrates, the flavin mono-oxygenases (FMO) can 
also catalyse the N- and S-oxygenation of a variety of xenobiotics (Krueger and Williams 
2005).  The FMO differ from CYP enzymes in that they do not contain a heme moiety 
(Kreuger and Williams 2005).  Alcohol dehydrogenases, aldehyde dehydrogenases and 
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epoxide hydrolases have also been reported to function in the metabolism of xenobiotics 
(Lash 1994).  Additional conjugative systems catalysing the acetylation (N-acetyl-
transferases, NAT), methylation (methyl-transferases) and conjugation with amino acids, 
such as glycine, are also present (Lohr et al 1998).   
 
1.1.7 Polymorphisms and drug metabolism 
The metabolism of endogenous and xenobiotic compounds (as described above) can occur 
by a variety of different pathways.  The tissue localisation, the broad and overlapping 
substrate specificity of different isoforms and systems, the concentration of substrate, and 
status of the organism or tissue (in terms of the levels and availability of co-factors such as 
PAPS or UDP-glucuronic acid) all determine which metabolic pathways occur for a particular 
substrate.  The above systems are also inducible, and can be regulated at the transcriptional, 
translational and post-translational levels by a wide variety of xenobiotics, which can result in 
a substrate increasing the rate of its own clearance by inducing the enzyme that metabolises 
it (Xu et al 2005).  The induction of genes involved in xenobiotic metabolism is mediated via 
nuclear receptors such as the Aryl hydrocarbon receptor (AhR), Pregnane X receptor (PXR) 
and Constitutive activated receptor (CAR), and is discussed further in Chapter 6 (Xu et al 
2005).  A further complicating factor in the metabolism of endogenous and exogenous 
compounds is that a large proportion of the enzymes involved in these pathways are 
polymorphic, which results in alternative forms of certain isoforms, resulting in alterations in 
the metabolic capabilities of different enzymes (Božina et al 2009).  There have been 
polymorphic variants identified of a wide variety of drug metabolism enzymes including CYP, 
UGT, SULT, GST and NAT isoforms, and due to the interactions between these different 
systems, there is substantial inter-individual variation in terms of the metabolism of a wide 
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variety of xenobiotic and endogenous compounds (Labuda et al 1999, van der Weide and 
Steijns 1999, Coughtrie 2002, Ehmer et al 2004, Sparks et al 2004, Blevins-Primeau et al 
2009).  The most clinically relevant examples of the affects of these polymorphic systems are 
CYP2D6 and NAT (Božina et al 2009).  The use of xenobiotics such as debrisoquine, 
dextromethorphan and sparteine for in vivo phenotyping of CYP2D6 has allowed to 
identification of ultra-rapid, extensive, intermediate and poor metaboliser phenotypes by 
determining the ratio of urinary metabolite and unchanged compound over a given time 
(Zanger et al 2004).  The identification of different variants of CYP2D6 that encode for a 
range of non-functional proteins (mainly premature terminations, but not exclusively, of the 
coding sequence), functional proteins that are somewhat compromised in enzyme activity, 
and altered coding sequences that result in excess production of the protein have been 
reported (Zanger et al 2004).  The existence of these different polymorphisms of the drug 
metabolism systems enzymes, in addition to the induction and inhibition of gene expression 
and enzyme activities by xenobiotics, contributes to the potential for a variety of different 
responses to xenobiotic exposures within a population.  
 
1.2 Zebrafish as a model organism 
Zebrafish are a well characterised model vertebrate in the fields of molecular genetics and 
developmental biology (Kimmel et al 1995).  Zebrafish embryos and larvae have been used 
to investigate molecular processes including angiogenesis, lipid metabolism, cardiac function 
and homeostasis (Langheinrich 2003).  A model of steatohepatitis in zebrafish treated with 
thioacetamide has also been reported, and the zebrafish has emerged as an alternative 
model organism in the field of Parkinsons’ Disease research and other neurodegenerative 
disorders (Amali et al 2006, Best and Alderton 2008, Flinn et al 2008, Flinn et al 2009).  
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Zebrafish are also being applied to modelling of the immune system (as they have both 
adaptive and innate immune systems) and to the field of oncology (Stern and Zon 2003, 
Berghmans et al 2005, Ceol et al 2008, Meeker and Trede 2008, Payne and Look 2009).  
The zebrafish is also becoming a popular model organism for toxicological screening, and 
zebrafish are a standard ecotoxicology testing species recommended by the Organisation for 
Economic Co-operation and Development (OECD) for fish toxicity testing as part of 
environmental risk assessments and hazard classification (Langheinrich 2003, OECD 2006).  
There have been a number of studies assessing a variety of different compounds for 
developmental toxicity including the widespread contaminant 2,3,7,8-tetrachlorodibenzo-p-
dioxin, which has not only been characterized for its effects upon the morphology and 
physiology of zebrafish embryos throughout development, but has also undergone extensive 
investigations into the molecular mechanisms of this toxicity (Carney et al 2006).  The 
advantages of zebrafish are listed in Table 1.2, with a particular focus upon zebrafish larvae.  
Adult zebrafish are also a useful model organism, especially now with the availability of the 
casper strain of zebrafish, which is a transparent adult fish, allowing in vivo imaging of 
fluorescent labels within the adult fish (White et al 2008).  Zebrafish larvae (>3 days post 
fertilization, dpf) are well-suited to drug discovery and toxicity testing assays, as these fish 
are hatched from the chorion, small in size, and the majority of major organs, such as liver, 
gills, heart, digestive system and locomotor responses have partially or fully formed, 
suggesting that the functions of these organs are in place (Kimmel et al 1995). 
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Table 1.2:  The advantages of zebrafish embryos and larvae as a model organism 
Characteristics Advantages and applications 
Rapid generation of large 
numbers of embryos 
100-200 embryos per female can be produced in a single 
spawning per week, allowing enough embryos for medium to 
high throughput screens. 
Transparent embryos and 
larvae 
Allows observation of organ development and morphology.  
Fluorescent tags (e.g. green fluorescent protein (GFP)), dyes 
and compounds can also be observed in vivo. 
Similarities in anatomy 
and physiology 
Vertebrate body plan and similarities in nervous, renal, 
cardiovascular, respiratory, gastrointestinal, endocrine, immune 
and reproductive systems to mammalian species. 
Similarities in sequence 
identity at protein level 
and pharmacology 
Sequence similarity approaching 100% in conserved regions of 
some proteins.  High level of functional conservation. 
Embryo and larval size 
Embryos and larvae (≤ 5 dpf) can be cultured in 96-well plates 
and in as little as 50 µl of water.  Applications to high throughput 
screening and reduces amounts of test compounds required thus 
reducing costs 
Husbandry costs 
Substantially lower than that for rodents.  Reported to be 1/100 
to 1/1000th of that for mice 
Genetic toolbox available 
Widespread use of transient gene knock-down and genetically-
modified fish (e.g. expressing GFP), sequenced genome which 
is becoming increasingly annotated.  Microarrays commercially 
available. 
Absorption of oxygen and 
compounds from water 
across the skin at early 
life-stages 
Zebrafish can survive for several days without a functioning 
circulatory system.  Compounds can be administered directly 
into the water allowing easy exposure of embryos and larvae to 
compounds 
Information collated from: Langheirich 2003, Goldsmith 2004, Lieschke and Currie 2007.   
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As a result of these characteristics of zebrafish larvae, there has been increasing interest in 
the application of these organisms as a pre-clinical testing species, with a view to functioning 
as an in vivo screen to reduce the number of compounds reaching mammalian testing and 
therefore drug development costs (McGrath and Li 2008).  The application of zebrafish larvae 
to the assessment of the effects of compounds upon cardiac output, locomotor activity, 
convulsant liability, gut motility, and the impairment of visual and auditory functions has been 
proposed, and some validation of these assays has been reported (Barros et al 2008, 
Berghmans et al 2008, Richards et al 2008, Winter et al 2008).  The assessment of the effect 
of 35 compounds upon visual response, assessed by the optomotor response (monitoring the 
swimming behaviour of zebrafish larvae in response to moving black and white stripes below 
the tank), reported 71% correct classification of compounds using data from in vitro and in 
vivo clinical models of retinal toxicity for comparison (Berghmans et al 2008, Richards et al 
2008).  A zebrafish assay to determine the seizure liability of compounds (by monitoring the 
swimming patterns of larval zebrafish) has been validated using a set of 25 compounds, with 
the correct classification (compared to in vitro and in vivo clinical models) of 72% of 
compounds reported (Winter et al 2008).  The validation of assays to assess cardiac toxicity, 
by measuring atrial and ventricular rates (78% correct classification using a set of 9 
compounds) and perturbation of gut motility, by measuring the frequency of gut contractions 
(correct classification of 60% using a set of 10 compounds) has also begun (Berghmans et al 
2008).  Although further validation of these types of assays is required, due to the low 
number of compounds used, the potential benefits of using such systems as pre-clinical in 
vivo toxicity screens is illustrated by these examples.  
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1.3 Comparison of drug metabolism genes and activities between mammals and 
fish 
Xenobiotic metabolism has substantial implications for disease modelling, ecotoxicology, 
toxicity testing and drug screening, due to the potential for the metabolic activation and 
deactivation of compounds.  All of these testing strategies utilise both in vitro (e.g. 
microsomal fractions from tissues, cultured cells or over-expressed proteins in yeast and 
bacteria) and in vivo systems (e.g. rodents species including mouse and rat, non-rodent 
mammals such as dogs, and environmentally-relevant species including fish, freshwater and 
marine invertebrates, and molluscs).  The comparison of drug metabolism systems between 
these model species and humans is a complex process, with substantial problems identifying 
direct homologues of human enzymes in non-mammalian (and indeed non-human) species 
due to the use of amino acid sequence identity as a determinant of similarity, rather than 
metabolic activity towards characteristic substrates.  This is illustrated in Appendix 1, by the 
alignments of the CYP1A1 amino acid sequence with the predicted zebrafish CYP1A 
sequence, and the alignment of the CYP2B6 and CYP2J26 (a gene identified as similar to 
human CYP2B6 – see chapter 3) from zebrafish (see appendix A1 and A2).  This is further 
complicated by the broad and overlapping substrate specificities of CYP, UGT, GST and 
SULT enzymes, resulting in some difficulty in identifying enzyme isoform specific marker 
reactions that can be used for screening. 
 
The CYP1, CYP2 and CYP3 family isoforms identified in the human (Homo sapiens), rat 
(Rattus norvegicus), mouse (Mus musculus), dog (Canis familiaris), zebrafish and Atlantic 
salmon (Salmo salar) genomes are listed in Table 1.3.  In addition to this, cytochrome P450 
genes have been identified in the freshwater invertebrate Daphnia pulex, other fish species 
including the European flounder (Platichthys flesus) and rainbow trout (Onchorynchus 
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mykiss), and a variety of insects and plants (Buhler and Wang-Buhler 1998, Williams et al 
2000, Baldwin et al 2009, Nelson 2009).  Although some comparisons can be drawn between 
species based upon gene sequences identified within the genomes of organisms, Table 1.3 
highlights that enzyme identification based upon predicted amino acid sequence is not 
sufficient to identify orthologous and homologous enzymes across different species. This 
results in a requirement for the comparison of enzymatic activities in order to compare 
metabolic capabilities across different species.  
 
There has been substantial investigations using in vitro preparations such as cultured cells, 
microsomal and cellular fractions from a wide variety of different tissues and fish species 
including Atlantic salmon, carp (Cyprinus carpio), channel catfish (Ictalurus punctatus), cod 
(Gadus mohua), dab (Limanda limanda), fathead minnow (Pimephales promelas) and 
rainbow trout (Varanasi et al 1987, Buhler and Wang-Buhler 1998, Morcillo et al 2004, 
Stuchal et al 2006, Fitzsimmons et al 2007, Matsuo et al 2008, González et al 2009).  These 
studies tend to use substrates such as ethoxy-resorufin, 7-ethoxy-coumarin, 7-pentoxy-
resorufin, carcinogenic compounds (e.g. benzo-[a]-pyrene), and endogenous hormones and 
steroids (e.g. oestradiol and testosterone) which are indicative of CYP-mediated metabolism, 
albeit with a lack of isoform specificity (Kern et al 1997, Kobayashi et al 2002).  Conjugative 
metabolism has also been assessed in a variety of different fish species, using substrates 
including 1-chloro-2,4-dinitrobenzene (GST), 2-trifluoromethyl-4-nitrophenol (UGT), p-
nitrophenol (UGT and SULT) and 1-naphthol (SULT, Fitzsimmons et al 2007).  Overall, these 
studies demonstrate that a variety of fish species possess similar types of metabolic 
capability as that observed for mammalian species however, there is a lack of isoforms 
specific characterisation, or identification of the isoforms(s) responsible for catalysing these 
processes, resulting in a lack of comparative data with mammalian systems.  
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Species CYP1 CYP2 CYP3 
Human 
(Homosapiens) 
1A1, 
1A2, 
1B1 
2A6, 2A7, 2A13, 2B6, 2B7, 2C8, 2C9, 2C18, 2C19, 2D6, 2D7, 2D8, 2E1, 2F1, 
2G1, 2G2, 2J2, 2R1, 2S1, 2T2, 2T3, 2U1, 2W1 
3A4, 3A5, 3A73, 3A43 
        
Rat (Rattus 
norvegicus) 
1A1, 
1A2, 
1B1 
2A1, 2A2, 2A3, 2B1, 2B2, 2B3, 2B12, 2B15, 2B21, 2B31, 2C7, 2C11, 2C12, 2C13, 
2C22, 2C23, 2C24, 2C79, 2C80, 2C81, 2D1, 2D2, 2D3, 2D4, 2D5, 2E1,  
3A1, 3A2, 3A9, 3A18, 
3A62, 3A73 
    2F4, 2G1, 2J3, 2J4, 2J10, 2J13, 2J16, 2R1, 2S1, 2T1, 2U1, 2W1, 2AB1, 2AC1   
        
Mouse (Mus 
musculus) 
1A1, 
1A2, 
1B1 
2A4, 2A5, 2A12, 2A22, 2B9, 2B10, 2B13, 2B19, 2B23, 2C29, 2C37, 2C38, 2C39, 
2C40, 2C44, 2C50, 2C54, 2C55, 2C65, 2C66, 2C67, 2C68, 2C69, ,  
3A11, 3A13, 3A16, 3A25, 
3A41, 3A44, 3A57, 3A59  
    2C70, 2D9, 2D10, 2D11, 2D12, 2D13, 2D22, 2D26, 2D34, 2D40, 2E1, 2F2, 2G1, 
2J5, 2J6, 2J7, 2J8, 2J9, 2J11, 2J12, 2J13, 2R1, 2S1, 2T4, 2U1, 2W1, 2AB1, 2AC1 
  
        
Dog (Canis 
familiaris) 
1A2 2A, 2A13, 2A6/7, 2B11, 2C21, 2C, 2C41, 2D15, 2E1, 2F, 2G1, 2J, 2R1, 2S1, 2T, 
2U1, 2W1, 2AB1, 2AC1,  
3A12, 3A26, 3A, 3A? 
        
Zebrafish (Danio 
rerio) 
1A, 1B1, 
1C1, 
1C2, 
1D1 
2J20, 2J21, 2J22, 2J23, 2J24, 2J25, 2J26, 2J27, 2J28, 2J29, 2J30, 2K6, 2K7, 2K8, 
2K16, 2K17 2K19, 2K20, 2K21, 2K22, 2N13, 2P6, 2P7, 2P8, 2P9, 2P10,  
3A65, 3C1/1, 3C1/2, 
3C1/3 
    2P12, 2R1, 2U1, 2X6, 2X7, 2X8, 2X9, 2X10, 2X11, 2Y3, 2Y4, 2AA1, 2AA2, 2AA3, 
2AA4, 2AA5, 2AA6, 2AA7, 2AA8, 2AD2, 2AD3, 2AD6, 2AE1,   
  
        
Atlantic salmon 
(Salmo salar) 
1A, 1B, 
1C, 1D 
2K, 2M1, 2M2, 2P, 2R1, 2U1, 2X, 2Y, 2AD, 2AE 3A 
 
Table 1.3:  A comparison of CYP1, CYP2 and CYP3 family isoforms identified in human (Homo sapiens), rat (Rattus novegicus), 
mouse (Mus musculus), dog (Canis familiaris), zebrafish (Danio rerio) and Atlantic salmon (Salmo salar).  The above table only 
lists annotated genes and does not include pseudogenes.  Genes were identified using the gene database at www.zfin.org and at 
the P450 homepage (Nelson 2009), accessed December 2009. 
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Unlike the majority of the fish species listed above and reviewed by Fitzsimmons et al 
(2007), zebrafish are well suited to the laboratory (see Section 1.2).  There are 89 CYP 
genes currently identified in zebrafish (compared to 57 in human, 102 in mouse and 54 in 
dog) , with 42 of these being members of the CYP2 family (Goldstone et al 2009, Nelson 
2009).  The metabolism of a variety of different CYP substrates by zebrafish 
homogenates (adult and larval tissues) is listed in Appendix 1 (Figure A3), and compared 
with both mammalian and non-mammalian species.  It is clear that although the 
metabolism of several non-specific CYP substrates has been demonstrated, these are 
mainly using adult and juvenile tissue homogenates (Troxel et al 1997, Arukwe et al 
2008).  A CYP3A activity, identified by the detection of a 6β-hydroxylation activity towards 
testosterone, has also been reported using primary hepatocytes from zebrafish (Reschly 
et al 2008).  It is clear from this list that zebrafish have not undergone exhaustive 
characterisation for CYP-mediated metabolism but that there is enough evidence to 
suggest, in adult fish, that similar metabolic systems to those found in mammalian species 
are present.  There is however a distinct lack of characterisation of such systems in 
zebrafish larvae (<7 dpf).  As it is these early life-stages of zebrafish that are being 
applied to toxicity testing, it is necessary that larvae at these stages of development are 
assessed for CYP activities.  A variety of CYP genes have been demonstrated to be 
expressed during mouse embryonic development and CYP3A7 is a human CYP isoform 
that is mainly detected in foetal tissues, therefore the expression of CYP isoforms during 
zebrafish development is not surprising (Choudhary et al 2003, Nishimura et al 2003).  It 
is currently thought that these expressed CYP isoforms have some role in normal 
embryonic development.  The expression of zebrafish CYP and UGT isoforms throughout 
development is discussed further in Chapter 3. Only EROD activity has been assessed in 
zebrafish larvae < 7 dpf, with Mattingly and Toscano (2001) reporting that EROD activity 
is only detected post-hatching, and Noury et al (2006) demonstrating a low activity 
towards ethoxy-resorufin using live larvae from a variety of different ages below 8 dpf.  
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Conjugative processes have also been assessed using zebrafish as a model species.  
The sulfotransferases have been extensively characterised for zebrafish, with 16 SULT 
isoforms (SULT1st1-8, SULT2st1-3, SULT3st1 and st2, SULT4a1, SULT6b1 and SULTX) 
currently identified in the zebrafish genome (www.zfin.org accessed December 2009, Liu 
et al 2005).  The SULT1, SULT2 and SULT3 genes have all been over-expressed in vitro, 
and characterised for substrate affinities towards endogenous and exogenous substrates, 
including oestrogens, flavenoids, thyroid hormone derivatives, hydroxychlorobiphenyls 
and dopamine (Ohkimoto et al 2003, Sugahara et al 2003, Liu et al 2005, Yasuda et al 
2005a, Yasuda et al 2005b, Yasuda et al 2006, Liu et al 2008, Yasuda et al 2008, Table 
1.4).  The expression of all of these identified SULT genes throughout development has 
been assessed by reverse transcriptase PCR (RTPCR), and has demonstrated that the 
different isoforms have distinct temporal patterns of expression throughout development 
(Ohkimoto et al 2003, Sugahara et al 2003, Liu et al 2005, Yasuda et al 2005a, Yasuda et 
al 2005b, Yasuda et al 2006, Liu et al 2008, Yasuda et al 2008).  It has also been 
reported that there is activity towards 1-chloro-2,4-dinitrobenze (a model substrate for 
GST activities) from both microsomal and soluble fractions of zebrafish embryos and 
larvae throughout development, with an increase in the activity of the soluble fraction 
towards this substrate post-hatching (Wiegand et al 2000).  Indeed, the glutathione 
conjugate of atrazine has been identified using enzyme extracts from zebrafish embryos 
(Wiegand et al 2001).  Although there have been 10 UGT sequences identified in the 
zebrafish genome, there is currently no evidence demonstrating the presence of UGT 
activities in embryonic or larval zebrafish (George and Taylor 2002).  However, Lindholst 
et al (2003) identified using adult zebrafish whole-body homogenates both the sulphate 
and glucuronic acid conjugates of bisphenol A.    
 
It is apparent that although there is evidence to suggest that fish species in general, and 
indeed zebrafish, possess similar xenobiotic metabolism pathways as those observed in 
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mammals, that particularly at embryonic and larval developmental stages (<7 dpf), further 
characterisation is required.  The majority of substrates that have been used in different 
fish species, such as ethoxy-resorufin, polycyclic aromatic hydrocarbons and aryl-amines, 
are promiscuous substrates or environmentally relevant carcinogens, and generally 
substrates of the CYP1 family enzymes.  There has been little investigation regarding the 
metabolism of pharmaceutical compounds by fish species, and with the application of 
zebrafish and other small fish species to toxicity testing this lack of knowledge needs to 
be addressed.  Although conjugative metabolism has been assessed in zebrafish, mainly 
the SULT enzymes and demonstration of GST activity towards the marker substrate 
CDNB, there is a lack of characterisation regarding the extent of UGT activity at 
embryonic and larval stages, and of activities towards pharmaceuticals. 
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Table 1.4: The characterisation of zebrafish SULT isoforms in vitro using over-expressed 
enzymes 
Enzyme pH dependency Substrates 
Modulation 
by metal 
ions? 
Temp. 
Tolerance 
(°C) 
SULT1 ST1 6-9 Hydroxychlorobiphenyls Y 40 
SULT1 ST2 4.5 and 10.5 
Hydroxychlorobiphenyls 
Esterone 
Dopamine 
17β-Oestradiol 
Phytoestrogens 
Y 
 
40 
SULT1 ST4 7 
Thyroid hormones 
Esterone 
Flavenoids 
Isoflavenoids 
Phenolic compounds 
Y 
 
<43 
SULT ST5 6 
Phenolic compounds 
Thyroid hormone derivatives 
Y  
SULT ST6 6.5 and 10.5 
Phenolic compounds 
Esterone 
17β-Oestradiol 
 
 
 
SULT2 ST1 9.5 
Steroids 
Neurosteroids 
Y 20 - 43 
SULT2 ST2 6.5 
DHEA 
Hydroxysteroids 
 
 
 
SULT2 ST3 6.5 
Corticosterone 
Hydroxysteroids 
  
SULT3 ST1 6.5 
17β-Oestradiol 
DHEA 
Diethylstilbestrol 
Bisphenol A 
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SULT3 ST2 5.5 
DHEA 
Pregnenolone 
17β-Oestradiol 
17α-Oestradiol 
 
 
 
SULT X 7.5 - 9.0 
Flavenoids 
phenolic compounds 
Isoflavenoids 
Dopamine 
Y 
 
40 
 
The biochemical assessment of different SULT isoforms in zebrafish.  Purified protein 
extracts for each isoform were assessed for pH dependency, substrate specificity, metal 
ion inhibition and temperature tolerance of activity.  Examples of phenolic compounds 
include β-naphthol, p-nitrophenol and n-propyl-gallate.  Metal ions include Fe2+, Zn2+, 
Co2+, Cu2+, Cd2+ and Hg2+.  Data from Ohkimoto et al 2003, Sugahara et al 2003, Liu et al 
2005, Yasuda et al 2005a, Yasuda et al 2005b, Yasuda et al 2006, Liu et al 2008, Yasuda 
et al 2008. 
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1.4 Aims of Project 
In order to characterise further xenobiotic metabolism in zebrafish at early life-stages (<7 
dpf), it was determined that, based upon the observations of Mattingly and Toscano 
(2001) and Wiegand et al (2000), larvae post hatching would be the most useful stage of 
development to undergo characterisation – as both Ethoxy-resorufin-O-deethylase 
(EROD) activity (as a marker of oxidative metabolism) and 1-Chloro-2,4-dinitrobenzene 
(CDNB) activity (a marker of conjugative metabolism) have been detected at these 
stages.  The zebrafish genes CYP1A, CYP2J26, zgc:153269 (CYP3A) and UGT1A1 were 
selected as representative genes of the CYP1, CYP2, CYP3 and UGT families and due to 
the sequence similarities with the human CYP1A1, CYP2D6, CYP3A5 and UGT1A1 
genes.  The broad CYP substrates ethoxy-resorufin, ethoxy-coumarin and 
octyloxymethylresorufin were selected to assess CYP activities in zebrafish because 
these substrates broadly reflect CYP1, CYP2 and CYP3 family activities in mammalian 
systems respectively, unlike pentoxy-resorufin which undergoes dealkylation catalysed by 
CYP1A2, CYP2B1 and CYP2C13 in rat (Kobayashi et al 2002).  The expression of SULT 
and GST genes and activities was not assessed in this study due to the extensive 
characterisation of these systems as discussed in chapter 1 (pages 27-31 and Weigand 
et al 2000).  Wik strain fish only were utilised in this project, as this strain is a widely used 
wild-type strain in the field of toxicology.  These fish were generously provided by Brixham 
Environmental Laboratory (AstraZeneca) and the University of Exeter to set up the 
zebrafish facility at The University of Birmingham. 
 
The aims of this project were as follows. 
1. To identify and assess the expression of genes similar to mammalian CYP1, 
CYP2, CYP3 and UGT1A1 throughout development. 
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2. Using an in vivo zebrafish larvae assay (96 hpf), assess the metabolism of the 
CYP and UGT substrates ethoxy-resorufin, ethoxy-coumarin and 
octyloxymethylresorufin by Wik strain hatched zebrafish larvae.   
3. Assess the modulation of the above activities by known inducers of drug 
metabolism genes (e.g. polychlorinated byphenyls) and in vitro inhibitors (e.g. α-
naphthoflavone and SKF525A). 
4. It is hypothesised that as zebrafish larvae have been demonstrated to posess 
some xenobiotic metabolism genes, larval zebrafish would be able to metabolise 
the NSAIDs acetaminophen and ibuprofen by oxidative and conjugative 
mechanisms similar to those described for mammals.  This hypothesis was tested 
in vivo, using a combination of liquid-chromatography-mass spectrometry and 
scintillation counting.  This study would also provide quantitative information. 
5. Determine the effects of the solvents dimethyl-sulfoxide and methanol exposures 
on the expression and activity of CYP enzymes in zebrafish larvae, since these 
are commonly used vehicles for substrates. 
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Chapter 2 
Materials and Methods 
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2.1  Maintenance of zebrafish and group spawning 
Mixed sex adult Wik strain zebrafish, approximately 9 months of age, were maintained at 
26 ± 1°C in groups of 20 fish in the husbandry unit at The University of Birmingham, with a 
light/dark cycle of 14/10 hours (290 – 300 Lux), respectively.  Fish were held in a 
Techniplast aquarium in dechlorinated town’s water, after filtration to 50 µm (mesh filter, 
biological filtration using Siprorax Grav ring biological filtration and mechanical filtration to 
50 µm – paper, Techniplast, Northampton, UK), and sterilisation (ultra violet – 30000 
µW/s/cm2).  Water was maintained at a conductance of 480 – 500 µS and at pH 7.4.  These 
groups were fed Artemia nauplii and zm200 (150 – 300 µm) –zm400 (500 - 800 µm) 
granulated feed (54% protein adult feed, ZMsystems Ltd, Winchester, UK).  The groups of 
fish were spawned and fertilised eggs were collected and maintained under the same 
conditions as adult fish, but at 28 ± 1°C, in accordance with the developmental staging of 
Kimmel et al (1995), until of a suitable age.  Zebrafish embryos and larvae were not 
deemed to be free-feeding until 5 dpf.  Under these conditions zebrafish embryos hatched 
from the chorion between 2 and 3 dpf. 
 
2.2  Exposure of zebrafish larvae (96 hpf) to Aroclor 1254 (CAS Number 11097-69-1), 
α-naphthoflavone (CAS Number 604-59-1 ), SKF525A (CAS Number 62-68-0), 
dimethyl sulfoxide only  or methanol only  
Zebrafish larvae (72 hours post fertilization, hpf) were incubated with 100 µg/l Aroclor 1254 
(dissolved in methanol – final solvent concentration of 0.05% v/v, Supelco lot # LA39006, 
Sigma-Aldrich, Schnelldorf, Germany), methanol only (0.05%, 0.01% or 0.001% v/v, HPLC 
grade, Fisher Scientific, UK) or dimethyl sulfoxide (DMSO) only (0.1% or 0.01% v/v, 
analytical grade, Fisher Scientific, UK) for 24 hours at 28 ± 1°C in dilution water (obtained 
from the Techniplast aquarium, The University of Birmingham) in 50 ml Falcon tubes.  After 
these exposures the larvae were utilized for RNA extraction, or for use in the assays for 
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xenobiotic metabolism as described in sections 2.3 and 2.5.  Zebrafish larvae (96 hpf) were 
incubated with α-naphthoflavone (1, 5 or 10 µM, dissolved in DMSO – final solvent 
concentration of 0.1% v/v), SKF525A (5 µM, dissolved in DMSO, final solvent concentration 
of 0.1% v/v) or 0.1% v/v DMSO only in dilution water, for the duration of the EROD, ethoxy-
coumarin-O-deethylase (ECOD) and octyloxymethylresorufin-O-dealkylase (OOMR) 
assays in 10 ml Falcon tubes (see section 2.6).   
 
2.3  RNA extraction from whole zebrafish embryos and larvae 
Total RNA was extracted from approximately 100 zebrafish larvae (24, 48, 72 and 96 hpf) 
using a QIAGEN RNeasy mini kit as directed in the manufacturer’s guidelines for tissue 
extraction (Qiagen, Crawley, UK).  Briefly, zebrafish larvae were homogenised in RLT 
buffer (containing β-mercaptoethanol) and centrifuged at maximum speed (16000g, 3 
minutes, room temperature) before the addition of 70% ethanol to the supernatant.  The 
supernatant was then added to an RNeasy spin column and centrifuged (8000g, 30 
seconds, room temperature), before washes with RW1 buffer and RPE buffer (8000g, 30 
seconds, room temperature).  The RNA was eluted in 100 µl of RNase-free water.  The 
isolated RNA was then electrophoresed on a 2.5% agarose gel to determine purity and 
quantified by spectrophotometry using a Nanodrop ND1000 (Thermo Scientific, LabTech, 
East Sussex, UK). 
 
2.4  The synthesis of cDNA, the Polymerase Chain Reaction (PCR), and Quantitative 
PCR (qPCR) 
From the isolated RNA, 500 ng of RNA was used as a template for cDNA synthesis.  A 
solution of RNA template, random hexamers (1 µl, Biolabs, Hertfordshire, UK) and 
nuclease-free water was heated to 65°C for 5 minutes.  To this solution 0.1 M DTT (2 µl), 
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First strand buffer (5 µl) and Superscript II reverse transcriptase (0.5 µl) from the Invitrogen 
Superscript II kit (Invitrogen, Paisley, UK) together with 25 mM dNTP mix (0.4 µl, Bioline, 
London, UK).  This was then incubated at 25°C for 10 minutes, 42°C for 90 minutes and 
70°C for 15 minutes in a thermocycler, before storage at -20°C.  The cDNA was quantified 
by spectrophotometry using a Nanodrop ND1000. 
The human sequences corresponding to CYP2B6, CYP3A5 and UGT1A1, as well as the 
zebrafish CYP1A, Aryl Hydrocarbon Receptor 1 and 2 sequences (Accession Numbers: 
NM_000767.4, NM_000777, NM_000463 and NM_131879), were used in a BLAST search 
of the zebrafish genome using the BLAST search at www.zfin.org (accessed February 
2008).  Primers were designed using the PRIMER3 software against sequences from 
zebrafish that had high similarity with the human genes (Table 2.1).  The primers for 
zebrafish RPL13α and EF1α were identified from the literature (Tang et al 2007). 
The synthesised cDNA was used as a template for PCR, using the primers designed 
against the target genes (Table 2.1).  The Bioline PCR kit was used for the PCR mix with a 
final volume of 50 µl (Bioline, London, UK).  The primers were diluted to a 10 µM stock 
solution for use with this reaction.  The genes of interest were amplified using a 
thermocycler program of 95°C for 5 minutes; 35 cycles of 95°C for 30 seconds, 60°C for 30 
seconds, 72°C for 30 seconds; 72°C for 5 minutes.  Products were electrophoresed on a 
2.5% agarose gel and visualised by ethidium bromide staining.  Fragment size was 
approximated using a 100 base pair marker ladder (New England Biolabs, Ipswich, UK). 
 
The PCR products were sequenced on a capillary sequencer ABI 3700 (The University of 
Birmingham Genomics Laboratory).  Fragments of the sequenced products were BLAST 
searched at www.zfin.org and genes with high similarity were identified.  This was used to 
confirm that the primers amplified the target genes of interest. 
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The validated primers were utilised in quantitative polymerase chain reaction (qPCR) 
assays using a Sensimix dT Sybr Green kit (Quantace, Finchley, UK).  A mastermix of 
50x Sybr green dye, 2x Sensimix and deionised water was added to 1 µl of each primer 
(10 mM) and 250 ng/µl of cDNA template, with a final volume of 25 µl per well, in a 96 well 
plate format.  Products were amplified and detected, following a dissociation protocol, with 
a program of 95°C for 30 seconds, 60°C for 30 seconds, using an Abiprism 7000 
sequence detection system.  The melt curves for all samples were analysed and Ct 
values were recorded for each gene in the linear phase of amplification.  Analysis of the 
data followed the ∆∆Ct method (Livak and Schmittgen 2001).  The efficiencies of the 
qPCR reactions were determined using the LinRegPCR software, as described by 
Ramakers et al (2003), in order to meet the requirements of the ∆∆Ct method of analysis.  
Three different cDNA samples, each synthesised from total RNA extracted from separate 
pools of 100 larvae, were analysed for each gene. 
 
2.5  In vivo fluorescence assays of xenobiotic metabolism 
The following assays were adapted and optimised from the ethoxyresorufin-O-deethylase 
assay protocol used in cell culture models as described by Green et al (2008).  Thirty 
zebrafish larvae (96 hpf) per time-point, were exposed in 10 ml Falcon tubes to 7-
ethoxyresorufin (8 µM, Sigma-Aldrich, Poole, UK), 7-ethoxycoumarin (100 µM, Sigma-
Aldrich, Poole, UK) or Vivid substrate octyloxymethylresorufin (OOMR, 8 µM, Invitrogen, 
Paisley, UK) dissolved in DMSO (0.1% v/v) for up to 10 hours in triplicate (five time-points 
per assay) in dilution water at 28 ± 1°C.  Dicumarol (10 µM, Sigma-Aldrich, Poole, UK) was 
added at each time-point, for the EROD and OOMR assays, to prevent degradation of the 
resorufin product by DT Diaphorase.  After incubation of the substrates, 750 µl of the water 
was added to 250 µl of either 100 mM sodium acetate buffer (pH 4.5) only or 250 µl of β-
glucuronidase/arylsulphatase extract (Roche, West Sussex, UK) diluted 666-fold with 100 
  
38 
 
mM sodium acetate buffer (pH 4.5) and incubated for 2 hours at 37°C.  The incubated 
mixture was transferred to a fluorescence curvette and 1 ml of 100% ethanol was added.  
The fluorescence of each sample was measured at the wavelengths detailed below using a 
Perkins Elmer LS50B fluorimeter.  Quantification of the fluorescence of each sample was 
determined using a standard curve of each product (resorufin and 7-hydroxycoumarin 
obtained from Sigma-Aldrich, Poole, UK), with the fluorescence determined under the 
appropriate conditions (resorufin λex = 530 nm, λem = 590 nm; 7-hydroxycoumarin λex = 368 
nm, λem = 456 nm).  No spontaneous formation of fluorescent product was observed for 
these assays. 
 
2.6  Fluorescence assays of xenobiotic metabolism with co-exposure to α-
naphthoflavone or SKF525A  
Zebrafish larvae were assessed for EROD, ECOD and OOMR activities, as described 
above (section 2.5) with the following modifications.  Zebrafish larvae (30 per replicate) 
were co-incubated with the substrate and inhibitor or 0.1% DMSO (solvent control) for 2 
hours (ECOD assay), 4 hours (EROD assay) or 10 hours (OOMR assay) before 
measurement of activity, as previously described (sections 2.2 and 2.5).  Activities were 
compared to the solvent control for calculation of the mean percentage inhibition. Both α-
naphthoflavone and SKF 525A were obtained from Sigma-Aldrich (Poole, UK).   
 
2.7  Exposure  of zebrafish larvae to ibuprofen and 14C-Ibuprofen  
Zebrafish larvae (72 hpf, 10 per replicate) were exposed to 100 µg 14C-ibuprofen/l 
(American Radiolabels Company, USA), or an ethanol solvent control.  Fish were exposed 
in triplicate for 0, 3, 6, 9, 12, 18 or 24 hours, at 28 ± 1°C, in 10 mls of dilution water (water 
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obtained from zebrafish aquarium system) in glass beakers.  These fish and water samples 
were then used for the assessment of 14C incorporation into larval tissues.    
Zebrafish larvae (72 hpf, 100 per replicate) were also exposed to 100 µg/l of ibuprofen 
(CAS Number 31121-93-4, Sigma, Poole, UK) or 14C-ibuprofen in triplicate, or an ethanol 
solvent control for 24 hours, at 28 ± 1°C.   Larvae were exposed in 10 ml volumes.  All 
stock solutions were made in ethanol and the solvent concentration was the same in all 
treatments (0.0015% v/v) which did not exceed that recommended by international testing 
guidelines (OECD, 1992). These larvae and water samples were used for the assessment 
of metabolism using LC-MS(MS).   
 
2.8  Assessment of 14C-incorporation in zebrafish larvae by scintillation counting 
After exposure, samples of the dilution water (1.5 ml) were collected using a pasteur pipette 
and stored at -80 ± 1°C in 2 ml microcentrifuge tubes until required for analysis.  Zebrafish 
larvae were removed from the dilution water and rinsed twice in HPLC grade water (Fisher 
Scientific, Loughborough, UK) before being homogenised manually between two 
microscope slides coated in scintillation fluid (Optiphase hisafe 3, Fisher Scientific, uk).  
The homogenate was then collected into an microcentrifuge using a cell scraper to collect 
all liquid from the microscope slides.  These slides were then rinsed using a small volume 
of scintillation fluid and 100 µl of 100% Triton X-100 (Sigma-Aldrich, Poole, UK) was added 
to the microcentrifuge tube, and made up to a final volume of 2 ml.  This was then vortexed 
thoroughly and incubated at room temperature overnight, followed by further vortexing.  
The water sample aliquots were defrosted on ice and added to scintillation fluid in a 1:7 
(sample:scintillation fluid ratio) up to a final volume of 2 ml.  Larval and water samples were 
then assessed for 14C content using a 5 minute count for 14C detection using a Packard 
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Tricarb 1600 TA Liquid Scintillation Analyser.  Results were recorded as disintegrations per 
minute (dpm). 
 
2.9  Extraction of larval samples exposed to ibuprofen for LC-MS(MS) analysis 
Zebrafish larvae were removed from dilution water and rinsed twice in HPLC grade water 
(Fisher Scientific).  The washed larvae were then homogenised in 500 µl HPLC grade 
dichloromethane (Fisher Scientific) using a Precellys 24 bead homogeniser (Precellys, 
Leicestershire, UK).  Homogenates were transferred into 1.5 ml micro-centrifuge tubes and 
centrifuged (9000 g, 30 mins, 4 ± 1°C).  The supernatant was retained and evaporated 
under nitrogen until dry.  Residues were then re-suspended in 100 µl methanol:acetic acid 
(12.5:0.1) in water (all reagents were HPLC grade, Fisher Scientific).  Extracts were then 
stored at -80 ±1°C, until required for analysis.  Samples of the dilution water used for 
exposures were retained and stored at -80 ±1°C until required for analysis. 
 
2.10  LC-MS(MS) analysis of larval extracts and water samples exposed to ibuprofen 
Water samples and larval extracts were separated by liquid chromatography, as detailed in 
Table 2.2.  Elutents were detected using a Finnigan LXQ-orbitrap (Thermo Electron 
Corporation) as detailed in Table 2.2.  The m/z for ibuprofen and its metabolites were 
detected in negative ion mode, and identified based on known metabolism in mammalian 
systems.  Accurate ion mass measurements and MS-MS fragmentation were recorded for 
the parent compound and any potential metabolites for ibuprofen exposed samples.   
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2.11 Exposure of zebrafish larvae to acetaminophen, and the extraction of these 
larvae for LC-MS analysis 
Zebrafish larvae (72 hpf, 100 larvae per replicate) were exposed in glass beakers to 60 µg/l 
or 500 µg/l acetaminophen dissolved in DMSO (Sigma-Aldrich, Poole, UK) or a solvent only 
(< 0.1% v/v DMSO), for 6 hours and 24 hours in triplicate.   
After these exposures, the zebrafish larvae were rinsed twice in HPLC grade water (Fisher 
Scientific), and homogenised in 500 µl of methanol using a Precellys 24 bead homogeniser 
(Precellys, Leicestershire, UK).  Homogenates were transferred into 1.5 ml micro-centrifuge 
tubes and centrifuged (9000 g, 30 mins, 4 ± 1°C).  The supernatant was retained and 
evaporated to dryness using a SPDIIIV concentrator with a RVT4104 refrigerated vapour 
trap (Thermo Electron Corporation).  Residues were re-suspended in 100 µl 
methanol:acetic acid (12.5% :0.1%) in water (all reagents were HPLC grade, Fisher 
Scientific).  Extracts were then stored at -80 ± 1°C, until required for analysis.  Samples of 
the dilution water used for exposures were retained and stored at -80 ± 1°C until required 
for analysis. 
 
2.12  LC-MS analysis of zebrafish larval extracts and water samples from the 
acetaminophen exposures 
Water samples and larval extracts were separated by liquid chromatography, as detailed in 
Table 2.3.  Elutents were detected using a Finnigan LXQ-orbitrap (Thermo Electron 
Corporation) as detailed in Table 2.3.  The m/z for acetaminophen and its metabolites were 
detected in positive and negative ion modes, and identified based on known metabolism in 
mammalian systems in addition to comparisons with acetaminophen sulfate and 
glucuronide analytical standards (Sigma-Aldrich, Poole, UK).   
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2.13  Scintillation counting of liquid chromatography fractions from larval extracts 
and water samples 
Larval extracts and water samples were separated into fractions (1 minute per fraction) 
using the LC method described above (Table 2.2) for the duration of the LC program.  
These fractions were added to 5 ml of scintillation fluid and assessed for 14C using a 20 
minute counting program on a Packard Tricarb 1600TA Liquid Scintillation Analyser.  
Radioactivity was expressed in Bequerels (Bq), and was quantified into nanomoles or 
picomoles based upon the specific activity of the radiolabel (1.85GBq / millimole) and 
corrected for a ratio of 14C:12C of 5.8:1 as determined using LC-MS(MS).  Any 14C detected 
by scintillation counting were compared to the retention times of metabolites identified 
using LC-MS(MS) to attempt to identify the nature of the 14C.     
 
2.14  Assessment of ibuprofen conjugation by scintillation counting 
Zebrafish larvae (15 per replicate) were exposed in glass beakers to 100 µg/l 14C-ibuprofen 
for 24 hours or solvent only as described in 2.11.  Larvae were rinsed twice in dilution water 
before homogenisation in 25 mM sodium acetate buffer (pH 4.5).  The homogenates were 
centrifuged (9000g, 30 minutes, -1°C) and the supernatant was retained.  Samples were 
divided into two groups (n=3 per group), with one group incubated with β-
glucuronidase/arylsulphatase mix (diluted 2664-fold, Roche, West Sussex, UK) and the 
other incubated without the addition of the β-glucuronidase/arylsulphatase enzyme mix for 
2 hours at 37°C.  Water samples (750 µl) from the exposures were added to 100 mM 
sodium acetate buffer (pH 4.5, 250 µl) and were incubated with or without the addition of 
the β-glucuronidase/arylsulphatase mix as for the larvae homogenates.  Both water and 
larval samples were extracted three times with dichloromethane (2 volumes of 
dichloromethane to every volume of sample) by vortexing (HPLC grade, Fisher Scientific), 
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with the dichloromethane extracts evaporated to dryness under a stream of nitrogen.  The 
residues were re-suspended in 150 µl of sterile water, and scintillation fluid was added in a 
1 : 7 ratio (Optiphase Hisafe 3, Fisher Scientific, West Sussex, UK).  The amount of 
radioactivity present in both the polar and non-polar fractions for each sample was 
determined using a 20 minute count for 14C detection using a Packard Tricarb 1600 TA 
Liquid Scintillation Analyser.  Results were recorded as disintegrations per minute (dpm) 
and converted into Bequerels (Bq), and expressed as a percentage of the total detected 
radioactivity in both polar and non-polar fractions for each sample. 
 
2.15  Statistical Analysis 
The data was assessed for normal distribution and homogeneity of variance by Sharipo-
Wilks’ test and Levenes’ test, respectively, using SPSS version 16 for Windows (SPSS, 
v.16).  Data that did not meet the requirements for normal distribution or homogeneity of 
variance were analysed by non-parametric statistics, using a Kruskal-Wallis test and Mann-
Whitney U test (SPSS, v.16).  Data that was normally distributed and met the criteria for 
homogeneity of variance was analysed by one-way ANOVA with a Tukey post-hoc test in 
SPSS or by independent samples t-test (v.16).  For analysis of real time PCR data, 
samples were analysed in triplicate using cycle threshold values (Ct) as described for 
fluorescence assays.  All graphs display the mean ± the Standard Error of the Mean (SEM).  
Values of p<0.05 were deemed to be significant.  A p-value of <0.05, <0.01 and <0.001 are 
indicated by *, ** and ***, respectively. 
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Table 2.1: Primers for use for the amplification of gene specific sequences of zebrafish 
CYP1A, CYP2J26, the CYP-gene zgc: 153269, UGT1A1, AhR1, AhR2, EF1α and 
RPL13α.   
Gene Left Primer Right Primer 
CYP1A TCC TGG AAA TCG GAA 
ACA AC 
CTG AAC GCC AGA CTC 
TTT CC 
CYP2J26 
 
AAG CCC ACA AAA ACC 
TCC CT 
ATA TCA TTG GAT GGG 
CGG TA 
zgc: 153269 (CYP3A) 
 
GGT GGA GGA GAT 
CGA CAA AA 
ACC GTT TTC TTA GCG 
GAC CT 
UGT1A1 
 
CTG CTG GTT GCA TTG 
AAG AA 
CGA TGA CGT CCA GAG 
AGT GA 
RPl13α 
 
TCT GGA GGA CTG TAA 
GAG GTA TGC 
AGA CGC ACA ATC TTG 
AGA GCA G 
EF1α 
 
CTG GAG GCC AGC TCA 
AAC AT 
ATC AAG AAG AGT AGT 
ACC GCT AGC ATT AC 
AhR1 
GTG ACC TCC AGT GGG 
ACA GT 
GGG GTA AAG CCA 
GGG TAG AG 
AhR2 
CCC TCA AGT GAC AGT 
GCT GA 
CTT GTT TTG CCC ATG 
GAG AT  
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Table 2.2. Liquid Chromatography Conditions and Mass Spectrometer Operating 
Parameters for the analysis of ibuprofen exposed larval extracts and water samples 
Column Waters Xbridge C18, 5 µm, 2.1 mm internal diameter 
Oven Temperature 30 ± 0.1 °C, Dionex Ultimate 3000 
Injection Volume 10 µl 
Elutant A 
Elutant B 
0.1% Ammonia in water 
Methanol 
Gradient (A:B) Time 0 min:        95%:5% 
Time 6 min:        0%:100% 
Time 8 min:        0%:100% 
Time 8.1 min:     95%:5% 
Time 11 min:      95%:5% 
Flow Rate 200 µl/min 
Autosampler Dionex Ultimate 3000 
Spray Voltage 3.0 kV 
Sheath Gas N2 at 40 arbitrary units 
Auxiliary Gas N2 at 10 arbitrary units 
Sweep Gas N2 at 0 arbitrary units 
Capillary Temperature 300°C 
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Table 2.3. Liquid Chromatography Conditions and Mass Spectrometer Operating 
Parameters for the analysis of acetaminophen exposed larval extracts and water samples 
Column Fortis Pace C18, 3 µm, 2.1 mm internal diameter 
Oven Temperature 30 ± 0.1 °C, Dionex Ultimate 3000 
Injection Volume 10 µl 
Elutant A 
Elutant B 
0.1% Ammonia in water 
Methanol 
Gradient (A:B) Time 0 min:        95%:5% 
Time 6 min:        0%:100% 
Time 8 min:        0%:100% 
Time 8.1 min:     95%:5% 
Time 11 min:      95%:5% 
Flow Rate 200 µl/min 
Autosampler Dionex Ultimate 3000 
Spray Voltage 3.0 kV 
Sheath Gas N2 at 40 arbitrary units 
Auxiliary Gas N2 at 1 arbitrary units 
Sweep Gas N2 at 0 arbitrary units 
Capillary Temperature 300°C 
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Chapter 3 
Oxidative and conjugative xenobiotic metabolism 
in zebrafish larvae in vivo 
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3.1 Introduction 
The zebrafish is a well characterised model vertebrate in the fields of molecular genetics 
and developmental biology, and is becoming a popular model organism in toxicology 
(Kimmel et al 1995, Langheinrich 2003).  There is also considerable interest in using 
zebrafish larvae as front-loading screens for drug discovery, with the assessment of toxic 
end-points including cardiac output, visual function and movement (Berghmans et al 
2008, Richards et al 2008, Winter et al 2008).  These studies have provided evidence that 
zebrafish larvae are a useful model system for predicting some human toxicity, albeit with 
a limited number of test compounds.  Assays assessing seizure liability, cardiac, 
intestinal, visual and locomotor function were reported as having 72%, 78%, 60%, 78% 
and 70% predictive toxicity, respectively, known from mammalian studies (Berghmans et 
al 2007, Richards et al 2008, Winter et al 2008).  A lack of bioavailability of compounds 
was implicated as a major reason for false negative predictions of toxicity, and this was 
demonstrated using quantitative Liquid Chromatography - Mass Spectrometry to measure 
uptake of the parent compound (Berghmans et al 2008).  However, it was not determined 
if there was any metabolism of the bioavailable test compounds and thus not established 
if metabolic activation or inactivation, in relation to toxicity, occurred.  In order for 
zebrafish larvae to be a useful test system for predicting potential human toxicity, it would 
be required that the larvae could metabolically activate compounds to toxic species.  
There is limited information regarding the presence of cytochrome (CYP) P450 isoforms 
or conjugation enzymes (these enzymes are responsible for the oxidative and conjugative 
metabolism of many pharmaceuticals, as well as endogenous compounds; Hersh and 
Moore 2004) in zebrafish, particularly in relation to expression at larval stages 
(summarised below, and extensively discussed in Chapter 1).   
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Although several different CYP genes have been identified and sequenced in the 
zebrafish, few of these enzymes have been tested for gene expression, induction and 
substrate specificity, to allow comparisons with mammalian CYP enzymes (Chung et al 
2004, Wang-Buhler et al 2005, Tseng et al 2005).  The identification of genes 
corresponding to CYP1, CYP2 and CYP3 mammalian genes is not surprising, as there 
have been several analogous genes and activities reported in different fish species 
(Williams et al 1998, Nabb et al 2006, Vaccaro et al 2007).  There is also a small number 
of reports of P450 activities identified in adult and juvenile zebrafish using whole-body or 
tissue homogenates (Chung et al 2004, Nabb et al 2006, Reschly et al 2007, Arukwe et al 
2008).  However, there is a lack of information regarding the activities of P450 enzymes in 
embryos and larvae, and it has been reported that EROD activity is only detected post-
hatch in zebrafish larvae (Mattingly and Tuscano 2001).  
 
To strengthen the justification for the use of zebrafish larvae in drug discovery and toxicity 
testing, it is essential that the status of xenobiotic metabolism be understood in this model 
species throughout development.  Therefore, the aims of this investigation were to identify 
genes homologous to mammalian CYP1, CYP2, CYP3 and UDP-Glucuronosyl 
Transferase (UGT) genes, and to assess the ability of zebrafish larvae in vivo to 
metabolise substrates used as markers for these enzymes in mammals.  The modulation 
of the identified genes and activities by a broad-acting inducing agent (Aroclor 1254, a 
mixture of polychlorinated biphenyls, PCB) and by known in vitro inhibitors of CYP 
enzymes was also assessed. 
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3.2 Methods 
Zebrafish larvae (72 hpf) were exposed to 100 µg/l of Aroclor 1254 (dissolved in methanol 
with a final volume of 0.05% v/v) or methanol only (0.05% v/v) for 24 hours in 50 ml of 
dilution water at 28 ±1°C where required (page 34, section 2.2).  RNA was extracted from 
100 embryos or larvae using a Qiagen RNeasy mini kit as directed by the manufacturer 
for extraction from tissues, and quantified by spectrophotometry using a Nanodrop 
ND1000 (page 35, section 2.3).    The extracted RNA was used to synthesise cDNA using 
the Invitrogen superscript II kit, using random hexamers for inital priming, and synthesised 
cDNA was quantified by spectrophotometry using a nanodrop ND1000.  Primers specific 
for the zebrafish genes CYP1A, CYP2J26, zgc:153269, RPl13α and EF1α were used to 
amplify these genes by PCR, with the identity of the products confirmed by sequencing, 
and also to quantify gene expression by qPCR using the Quantace sensimix dT kit and 
analysed by the ∆∆Ct method (section 2.4 page 35).  Zebrafish larvae were assessed for 
EROD, ECOD and OOMR activities by the addition of the appropriate substrate (8 µM 
ethoxy-resorufin, 100 µM ethoxy-coumarin, or 8 µM octyloxymethylresorufin, all dissolved 
in DMSO with a final volume of 0.1% v/v) to 30 larvae (96 hpf) for up to 10 hours in 1 ml of 
dilution water.  Dicumarol (10 µM) was also added in the EROD and OOMR assays.  After 
incubation with the substrate, 750 µl of the assay medium was removed and added to 250 
µl of 666-fold diluted β-glucuronidase/arylsulfatase (in 100 mM sodium acetate buffer, pH 
4.5) or just buffer only, and incubated for 2 hours at 37 ± 1°C.  Ethanol was added to the 
the solution (1 ml) and fluorescence was measured at the appropriate wavelengths 
detailed in section 2.5, page 37.  The EROD, ECOD and OOMR assays were also used 
to assess the effects of α-naphthoflavone and SKF525A by co-incubating the assay 
substrates with the appropriate inhibitor (dissolved in DMSO, final volume 0.1%) for 2 
hours (ECOD assay), 4 hours (EROD assay) and 10 hours (OOMR assay, page 38, 
section 2.6).  These methods are further detailed in chapter 2.   
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3.3 Results 
3.3.1 The identification of cytochromes P450 and UDP-glucuronosyl transferase genes 
in the zebrafish 
The human genes CYP2B6 (NM_000767.4), CYP3A5 (NM_000777) and UGT1A1 
(NM_000463) were selected as representative genes of CYP2, CYP3 and UGT classes, 
respectively, and used as a template for the identification of similar genes in zebrafish.   
Using a BLAST search (www.zfin.org) of the zebrafish cDNA/RNA sequence database 
(accessed February 2008), the genes CYP2J26 (zgc:91790), the CYP-gene zgc:153269 
and UGT1A1 (zgc:123097) were identified as being most homologous to the human 
genes.  The zebrafish CYP1A gene (zgc:109747) has previously been identified and 
extensively characterised.  Primers for each of the genes identified in the zebrafish were 
designed using the Primer3 software (http://frodo.wi.mit.edu/primer3/)  and determined to 
be specific for each gene by sequencing of PCR products.  The sequences of the PCR 
products were used as a template for BLAST searches of the zebrafish cDNA/RNA 
sequence database (www.zfin.org), and all identified the genes that the primers were 
designed against.    All of these genes were found to be expressed by zebrafish larvae at 
96 hpf. 
 
3.3.2 Developmental expression of zebrafish CYP and UGT genes assessed by RTPCR 
The expression of the CYP1A, CYP2J26, the CYP-gene zgc:153269 (CYP3 and UGT1A1 
was assessed across development by RT-PCR at 24, 48, 72 and 96 hpf (Figure 3.1).  The 
CYP1A gene was expressed at all timepoints that were assessed, and appeared to 
increase in expression throughout the timecourse.  The CYP2J26 gene also showed a 
steadily increasing expression pattern throughout the developmental timecourse 
assessed.  The gene zgc:153269 (CYP3) seemed to be more highly expressed at 24 hpf, 
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with lower expression detected by 48 hpf and increasing through to 96 hpf, whereas 
UGT1A1 was highly expressed from 48 hpf onwards.  All these genes showed an 
increase in expression after 48 hpf, which coinsides with when embryos begin to hatch 
from their chorions, and would thus coincide with increased exposure to xenobiotics. 
 
3.3.3 Activities towards ethoxyresorufin (EROD), ethoxycoumarin (ECOD) and 
octyloxymethylresorufin (OOMR) in vivo in zebrafish larvae 
Having determined that zebrafish larvae express CYP1, CYP2, CYP3 and UGT genes 
throughout embryonic development, and due to reports that EROD activity is not detected 
until post-hatching (Mattingly and Tuscano 2001), it was determined that 96 hpf larvae 
would be used for the assessment of CYP activities in vivo.  It should be noted that these 
assays reflect the processes of absorption, metabolism and excretion, as the larvae are 
intact and alive throughout the incubations.  Also, the three substrates used in this study 
are metabolised by multiple different CYP isoforms in mammalian systems, therefore 
enzyme kinetic analyses could not be included within these assays.  Correlations of the 
amount of product yielded per larvae over time have been generated to demonstrate the 
time-dependent increases in fluorescent product formation.  
A time-dependent increase in fluorescence, corresponding to the detection of resorufin, 
was observed for larvae exposed to ethoxyresorufin in the EROD assay (Figure 3.2).   
Incubation of the surrounding medium with a β-glucuronidase/arylsulphatase preparation 
resulted in a significant increase in the detection of resorufin compared to media 
incubated with buffer alone (p<0.001, Kruskal-Wallis test).  This demonstrated that 
zebrafish larvae (96 hpf) metabolise ethoxyresorufin to resorufin, a CYP1-dependent 
process in mammals, and also conjugate resorufin.    
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Figure 3.1:  The developmental expression of zebrafish CYP1A, CYP2J26, zgc:153269 
(CYP3A) and UGT1A1 in zebrafish larvae.  Total RNA was extracted from a pool of 100 
larvae, which was used for cDNA synthesis.  Equal amounts of cDNA (1 µg per sample to 
ensure equal loading, thus a reference gene was not required) was used as a template for 
PCR amplification of the above genes across normal embryonic development.  Three 
independent experiments were assessed, with the above image being representative of 
these experiments.   
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The metabolism of 7-ethoxycoumarin to 7-hydroxycoumarin (ECOD assay) is a general 
marker for CYP2 activities in mammals.  A time-dependent increase in the production of 
7-hydroxycoumarin was observed with larvae incubated with 7-ethoxycoumarin (Figure 
3.3A).  The comparison of excreted product detected with and without the use of the 
deconjugation enzymes was statistically significant (Figure 3.3B, p<0.05, Kruskal-Wallis 
test), with significant differences between deconjugated and not deconjugated samples 
observed at 1, 2 and 4-hour time-points (p<0.05 for all comparisons, Mann Whitney U 
test).  The conversion of octyloxymethylresorufin to resorufin was used as a substrate for 
CYP3-mediated metabolism.  A time-dependent increase in resorufin production was 
observed (Figure 3.4).   
 
3.3.4 The induction of CYP and UGT gene expression, and EROD activity by Aroclor 
1254 
After exposure to 100 µg/l Aroclor 1254 for 24 hours, the genes CYP1A, the CYP-gene 
zgc:153269 (CYP3) and UGT1A1 appeared to be induced based upon a 5-fold, 2-fold and 
3-fold increase in expression compared to the methanol solvent control, respectively 
(Figure 3.5). However, these apparent increases were only supported in the case of 
CYP1A by statistical significance (p<0.01, independent samples t-test), and CYP2J26 
was neither induced or repressed by Aroclor 1254 exposure.  The two reference genes, 
elongation factor 1α and Ribosomal protein l13α, were both found to be modulated by 
either methanol or Aroclor 1254 exposure, and thus were not used during the analysis of 
the data, with CYP2J26 being used as a reference gene.  It was also observed that, by 
comparison of the methanol solvent control to untreated samples, methanol exposure 
repressed the expression of CYP1A, the CYP-gene zgc:153269 (CYP3) and UGT1A1.  
This solvent effect is being investigated further in zebrafish and other species (see 
Chapter 5).   
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Figure 3.2: EROD assay. Thirty zebrafish larvae (96 hpf) per time-point were incubated 
with 8 µM 7-ethoxyresorufin over 10 hours at 28 ± 1°C, ± β-glucuronidase/arylsulphatase 
digestion of excreted product for 2 hours at 37 ± 1°C.  Each point on the graph represents 
the mean ± SEM (n = 3 separate experiments).  * and ** indicate p<0.05 and p<0.01, 
respectively. 
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The effect of Aroclor 1254 exposure on EROD activity was also assessed, and compared 
with a methanol solvent control.  A significant induction of EROD activity was observed 
(p<0.005, Kruskal-Wallis test), although as observed for the expression of CYP genes 
exposure to methanol repressed EROD activity compared to untreated larvae (Figure 
3.6). 
 
3.3.5 The effects of CYP inhibitors α-naphthoflavone and SKF525A on EROD, ECOD 
and OOMR activity in vivo 
Exposure of larvae to increasing concentrations of α-naphthoflavone for the duration of 
the EROD assay resulted in a dose-dependent induction in resorufin production 
compared to solvent controls (Figure 3.7A, p<0.05 for 5 and 10 µM exposures).  Co-
exposure of SKF525A with ethoxycoumarin did not cause any significant inhibition of 
ECOD activity (Figure 3.7B), however, OOMR activity was significantly increased with co-
exposure of substrate and SKF525A (p<0.05, Mann Whitney U test, Figure 3.7B), 
indicating an inability to show CYP inhibition due to induction in the in vivo assay.   
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Figure 3.3: ECOD assay.  Thirty zebrafish larvae per time-point were incubated over 8 
hours with 100 µM 7-ethoxycoumarin before deconjugation by β-
glucuronidase/arylsulphatase at 37 ± 1°C for 2 hours (A) and the comparison of ECOD 
activity with and without deconjugation (B).  Each point on the graph represents mean ± 
SEM (n = 3 separate experiments). * indicates p<0.05. 
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Figure 3.4:  OOMR Assay.   Thirty zebrafish per time-point were incubated with the 
OOMR substrate for up to 10 hours at 28 ± 1°C before deconjugation by β-
glucuronidase/arylsulphatase at 37 ± 1°C for 2 hours.  Each point on the graph represents 
the mean ± SEM (n = 3 separate experiments).   
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Figure 3.5:  The expression of zebrafish genes CYP1A, zgc:153269 (CYP3A) and UGT1 
was assessed following treatment with Aroclor 1254 (100 µg/l for 24 hours) compared to 
changes induced by 0.05% v/v methanol (solvent control) by qPCR.  Gene expression 
was normalised to that of CYP2J26, as the expression of this gene was unaffected by 
either treatment (100 pooled larvae per sample; n = 3; mean ± SEM).  ** Indicates p<0.01. 
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Figure 3.6:  EROD assay for zebrafish larvae with deconjugation (as described in the text) 
after a 24-hour pre-treatment with methanol only (0.05% v/v) or Aroclor 1254 (100 µg/l 
dissolved in methanol) (30 pooled larvae per time-point; n = 3 separate experiments; 
mean ± SEM).  * Indicates p<0.05. 
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Figure 3.7:  The effects of α-naphthoflavone and SKF525A on EROD, ECOD and OOMR 
activities in zebrafish larvae (96 hpf).  Zebrafish larvae (30 larvae per replicate) were 
exposed to the appropriate substrate and inhibitor for 2 hours (ECOD assay), 4 hours 
(EROD assay) or 10 hours (OOMR assay) and assessed for product formation.  Figure A 
shows the effect of α-naphthoflavone exposure upon EROD activity.  Figure B shows the 
effect of SKF525A upon ECOD and OOMR activities.  The graphs show mean percentage 
of the solvent control ± SEM (n = 3 separate experiments).  * Indicates p<0.05. 
 
* 
* 
* 
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3.4 Discussion 
This study has assessed the expression of genes that have been identified as similar to 
mammalian CYP1A, CYP2B6, CYP3A5 and UGT1A1.  There have been many CYP 
genes identified in the zebrafish genome, however the expression of genes similar to the 
mammalian genes responsible for xenobiotic metabolism is less well studied.  There is 
also substantial difficulty identifying zebrafish orthologs to mammalian CYP genes, due in 
part to the criteria for CYP identification being based upon similarities in sequence identity 
to mammalian genes, and also in part to the larger number of CYP genes present in the 
zebrafish genome.  Goldstone et al (2009) have reported identifying 89 CYP genes in the 
zebrafish genome compared with the 57 CYP genes in the human genome, 
http://drnelson.utmem.edu/CytochromeP450.html).  As a result of these difficulties, based 
upon sequence identity, the genes CYP2J26 (zgc:91790), the CYP-gene zgc:153269 and 
UGT1A1 (zgc:123097) were identified as orthologs to the mammalian CYP2B6, CYP3A5 
and UGT1A1, respectively.  This identification has not considered any functional 
similarities or substrate specificity, and is based purely upon gene sequence similarity.  
These genes were selected to be representative of the key mammalian families 
responsible for the oxidative metabolism of a variety of pharmaceuticals, and expression 
was assessed throughout development.  Gene expression appears to broadly increase 
throughout normal embryonic development, with higher expression observed in larvae 
post-hatching.  Each of the different CYP genes assessed showed distinctive patterns of 
expression, with that observed for CYP1A gradually increasing throughout development, 
in agreement with previously published expression time-courses in zebrafish (Jőnsson et 
al 2007).  The CYP-gene zgc:153269 was observed to have an expression pattern 
different to those observed for CYP3A65 and CYP3C1 in zebrafish, with higher 
expression of the gene at 24 hpf than at 48 or 72 hpf, with an increase in expression by 
96 hpf (Corley-Smith et al 2005, Tseng et al 2005), whereas the expression of CYP2J26 
and UGT1A1 has not previously been assessed throughout development in zebrafish.  In 
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this study, both these genes gradually increase in expression throughout early 
development (24-96 hpf).  The observation that CYP-genes are expressed in distinct 
patterns is consistent with the observation of distinct and specific patterns of expression in 
embryonic and newborn mice (Choudhary et al 2005, Hart et al 2009).  Goldstone et al 
(2009) have also reported that the majority of CYP genes in zebrafish have distinct 
temporal patterns of expression throughout development.  It has been proposed that 
although the CYP1-3 family enzymes are generally regarded as xenobiotic-metabolising 
enzymes, due to these distinct expression patterns seen throughout development, that 
these genes have a critical role in normal embryonic development (Choudhary et al 
2004).  Indeed, it has been shown that CYP1B1 is required for the normal development of 
the eye (Choudhary et al 2007).  The CYP1-3 families have also been reported to 
metabolise a range of endogenous signalling molecules implicated in embryonic 
development, such as steroids, retinoid, fatty acids and vitamin D (Choudhary et al 2004).  
It is thus possible that the observed temporal patterns of expression for the identified CYP 
genes in zebrafish have a role in endogenous molecule signalling required for normal 
development.  It has also been demonstrated that CYP1A was significantly induced.  The 
CYP-gene zgc:153269 (CYP3) and UGT1A1 also had a higher level of expression, albeit 
not statistically significant, after exposure to Aroclor 1254, a known modulator of drug 
metabolism genes, whereas CYP2J26 levels were not altered.   
Activities towards 7-ethoxyresorufin, 7-ethoxycoumarin and octyloxymethylresorufin were 
detected in an in vivo assay format.  These assays required the uptake, metabolism and 
excretion of the substrates for any activity to be detected, and each substrate is a broad 
marker for CYP1, CYP2 and CYP3 families respectively.  Due to these considerations, 
kinetic analysis of the enzyme activity per se could not be attempted.  The excretion of the 
fluorescent products into the surrounding media is required for the detection of activity in 
these assays.  Zebrafish have been reported to express ABC transporter proteins such as 
multidrug resistance protein 1 (MDR1) in adult livers, and the ABC transporter inhibitor 
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cyclosporine A causes a substantial increase in rhodamine B accumulation in zebrafish 
embryos (24 hpf, Bresolin et al 2005, Scholz et al 2008).  In addition to the presence of 
drug transporters, organs important for the excretion of compounds such as the gills 
develop from 72 hpf onwards (Kimmel et al 1995).  The use of 7-ethoxyresorufin as a 
substrate in a live larval zebrafish assay has been previously reported by Noury et al 
(2006), and EROD activity has also been assessed using fluorescence microscopy in 
Japanese medaka and zebrafish larvae (Carney et al 2004, Billard et al 2006, Carney et 
al 2008).  The rate of product formation observed by Noury et al (2006) is similar to that 
calculated for a linear trend reported in this study (2.93 fmoles/larvae/minute) however, 
this does not take into account conjugative (phase II) metabolism, as resorufin has been 
reported to undergo glucuronidation which prevents the detection of the fluorescent 
product (Behrens et al 1998).  The use of β-glucuronidase/arylsulphatase resulted in an 
approximately 6-fold increase in the amount of product formation over a period of 10 
hours, and demonstrated that substantial phenolic conjugation was occurring.  The 
metabolism of 7-ethoxycoumarin to 7-hydroxycoumarin has been associated with several 
mammalian CYP2 isoforms including CYP2B, CYP2C and CYP2E1 (Kern et al 1997).  
Significant conjugative (phase II) metabolism was also demonstrated in this assay.  These 
demonstrations of phenolic conjugation are the first, to the knowledge of the author, of 
these processes functioning in vivo in zebrafish larvae. Octyloxymethylresorufin 
metabolism to resorufin is primarily catalysed by CYP3A4 and CYP3A5 isoforms, and the 
detection of activities towards both of these substrates for zebrafish larvae suggests that 
these larvae possess systems similar to CYP2 and CYP3 family enzymes.  The non-linear 
increases in fluorescence observed in the ECOD and OOMR assays have been attributed 
to the metabolism of ethoxy-coumarin and octyloxymethylresorufin by multiple CYP 
isoforms.  The demonstration of phenolic conjugation in the EROD and ECOD assays is 
the first in vivo demonstration of this process in zebrafish larvae known to the author.  The 
observation that zebrafish larvae can metabolise broad specificity CYP substrates in vivo 
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agrees with the reported metabolism of 7-ethoxyresorufin by larval homogenates and the 
CYP3A-specific 6β-hydroxylation of testosterone in zebrafish primary hepatocytes 
(Mattingly and Toscano 2001, Reschly et al 2008).  Whole-body homogenates of 
zebrafish larvae have been reported to have a basal EROD activity of 2.5 pmol/min/mg 
protein (3 dpf, post-hatching) and 5.5 pmol/min/mg protein (4 dpf) respectively (Mattingly 
and Toscano 2001).  Other substrates with broad specificities such as methoxyresorufin, 
pentoxyresorufin and benzyloxyresorufin have been used to assess CYP activities in 
microsomal preparations from zebrafish fry that are free-feeding (>5 dpf, Aukwe et al 
2008).  Taken together, the work presented here demonstrates that zebrafish larvae (<5 
dpf) express genes and have activities similar to those observed in mammalian systems 
for the metabolism of xenobiotics, as has been observed for zebrafish at later stages of 
fish development.  The detection of these enzyme activities co-incides with increased 
expression of CYP and UGT genes during the development of these early life stages. 
 
The modulation of EROD activity in vivo by α-naphthoflavone and Aroclor 1254 was also 
assessed.  Pre-exposure to Aroclor 1254 for 24 hours resulted in the induction of EROD 
activity compared to a methanol solvent control.  This observation is consistent with the 
observed induction of CYP1A gene expression, and the reported effects of 
polychlorinated biphenyls on fish species, although adult zebrafish have been reported to 
be insensitive to EROD induction by Aroclor 1254 exposure (Troxel et al 1997, Borlak and 
Thum 2001).  Induction of CYP1A is mediated via the aryl-hydrocarbon receptor and this 
regulatory system has been extensively studied in zebrafish, with AhR agonists such as 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), β-naphthoflavone and a mixture of 
polychlorinated biphenyls inducing CYP1 gene expression and EROD activity (Hahn 
1998, Örn et al 1998, Carney et al 2006, Jőnsson et al 2007).  It should be noted that 
there was an observed inhibitory effect of methanol, which was used as a solvent for the 
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Aroclor 1254 (as supplied), at both the gene expression and enzyme activity levels.  The 
basis of this modulation is further investigated and discussed in Chapter 5.  It has also 
been demonstrated that the in vitro CYP1 inhibitor α-naphthoflavone also induces EROD 
activity in a dose-dependent manner using the in vivo EROD assay.  Although it would be 
expected that α-naphthoflavone would inhibit EROD activity, it should be noted that α-
naphthoflavone is a weak agonist for the aryl hydrocarbon receptor in zebrafish, and has 
been shown to induce CYP1 gene expression in larvae (Timme-Laragy et al 2007).  
Billard et al (2006) have also reported that exposure to α-naphthoflavone alone does not 
inhibit EROD activity in vivo using 96 hpf zebrafish larvae.  The studies of Timme-Laragy 
et al (2007) and Billard et al (2006) used fluorescence microscopy to assess the 
accumulation of resorufin in the gastro-intestinal tract as a measure of EROD activity, and 
therefore may not account for the amount of conjugated resorufin present, whereas this 
study has observed an induction in the total amount of resorufin excreted (including 
conjugated resorufin) upon co-exposure to α-naphthoflavone.  As a 4-hour co-exposure of 
α-naphthoflavone with the substrate was utilized in this work it also suggests that the 
observed induction of EROD activity is a rapid process. 
The in vitro CYP inhibitor SKF525A had a very minor inhibitory effect upon ECOD activity 
in zebrafish larvae over 2 hours exposure.  It is possible that this is because there was 
insufficient time for uptake of the inhibitor, however, it has also been demonstrated that 
SKF525A can induce CYP activities in vivo, such as OOMR activity, and thus the 
inhibitory effects of this compound could not be demonstrated.  Although SKF525A is a 
general CYP inhibitor in vitro, it has been reported that SKF525A induces both 
pentoxyresorufin-O-depentylase (PROD) and EROD activities in B6C3F1 mice (Jeong et 
al 2004).  These observed increases in CYP activities highlight the differences in 
complexity between in vitro systems, such as tissue or whole organism homogenates, 
and in vivo systems where there is potential for inhibitory compounds to function as 
inducing agents via agonistic interaction with nuclear receptors.  Overall, the modulation 
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of CYP activities in zebrafish by inhibitors of CYP enzymes reflects the complexity of 
combined inhibitory and inducing effects in vivo.  The demonstration of the potential of 
compounds such as α-naphthoflavone to have a mix of inhibitory and inducing effects in 
vivo also has implications in environmental monitoring.  EROD activity is routinely used as 
a biomarker in aquatic species for assessing exposure to polyaromatic hydrocarbons, 
polychlorinated biphenyls and other organic contaminants (Sarkar et al 2006).  The 
potential for a chemical to both induce and inhibit EROD activity could result in a minimal 
or lack of response to exposure, and thus potentially make EROD activity an unreliable 
biomarker. 
 
For zebrafish larvae to be a useful model organism in toxicity testing it is important that 
human metabolic processes are reflected by the zebrafish system.  As discussed 
previously, it is difficult to identify orthologous genes to the mammalian CYP complement, 
and the identification of such genes provides no information regarding functional activities 
or substrate specificities.  As discussed in both the general introduction and this chapter, 
EROD, ECOD and OOMR are substrates for a wide range of CYP isoforms and the 
demonstration of their metabolism in zebrafish larvae suggests that there are some 
similar activities between zebrafish and mammals.  However, due to the lack of isoform 
specificity of these substrates, it is difficult to draw direct comparisons with mammalian 
systems.  The use of isoform-characteristic reactions such as the 6α-hydroxylation of 
Paclitaxel (CYP2C8), tolbutamide hydroxylation (CYP2C9), the hydroxylation of coumarin 
(CYP2A6), and the 6β-hydroxylation of testosterone (CYP3A4), would further highlight 
similarities and differences between mammals and the zebrafish (Brown et al 2008).  The 
metabolism of some common pharmaceuticals, such as ibuprofen (CYP2C8/9-catalysed 
hydroxylation) and the oxidation of paracetamol to N-acetyl-p-benzoquinoneimine 
(CYP2E1 and CYP3A4) have also been linked with a limited number of specific CYP 
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isoforms and could be used not only to demonstrate pharmaceutical metabolism, but to 
determine similarities in substrate specificities of mammalian and zebrafish xenobiotic 
metabolism systems (Kepp et al 1997, Tonge et al 1998).  Overall, this study provides 
further evidence that zebrafish larvae express genes and activities similar to mammalian 
systems responsible for xenobiotic metabolism.  Both oxidative and conjugative 
metabolism have been demonstrated, as has the inducibility of EROD activity by AhR 
agonists in vivo, supporting application of this model in toxicological testing and drug 
discovery and the use of zebrafish larvae for ecotoxicology testing. 
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Chapter 4 
 
The assessment of non-steroidal anti-inflammatory 
drug (NSAID) metabolism by zebrafish larvae 
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4.1 Introduction 
Chapter 3 demonstrated the presence of xenobiotic metabolism genes and enzyme 
activities similar to those identified in mammalian species in zebrafish larvae.  However, 
further characterisation of these drug metabolism systems using more selective enzyme 
substrates and the demonstration of the metabolism of pharmaceuticals is required to 
further characterise the utility of these organisms in toxicity testing.  The metabolism of 
pharmaceuticals by fish also has implications for the fate of these materials in the aquatic 
environment.   
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used analgesics in both 
human and veterinary medicines.  This class of pharmaceutical includes drugs such as 
diclofenac, acetaminophen and ibuprofen.  The metabolic degradation of ibuprofen (2-[4-
(2-methylpropyl)phenyl]propanoic acid) is well-described in mammals, involving oxidation 
of the parent compound to hydroxy-ibuprofen and carboxy-ibuprofen, and conjugation 
with glucuronic acid of both parent and metabolite compounds (Kepp et al 1997, Figure 
4.1).  The oxidation of ibuprofen is catalysed by the CYP2C8/9 isoforms in humans 
(Brown et al 2008).  The metabolism of acetaminophen (N-(4-hydroxyphenyl)acetamide) 
can involve the direct conjugation of the parent compound to either glucuronic acid or 
sulfate moieties, as well as oxidative metabolism by CYP 2E1 and CYP2A6 (Graham et al 
2005, Figure 4.2).  It has also been suggested that CYP1A2 and CYP3A4 may have a 
role in the metabolism of acetaminophen into its toxic derivative N-acetyl-p-
benzoquinoneimine (NPBQI), although the CYP2E1 isoform has been implicated in vivo 
as the major isoform for this metabolism in human volunteers administered therapeutic 
doses of acetaminophen (Chen et al 1998, Tonge et al 1998, Manyike et al 2000).  This 
results in the metabolic activation of this compound to a toxic intermediate, that can cross-
react with proteins, deplete cellular thiols, induce oxidative stress and result in damage to 
the liver (Pirmohamed 2008).  Due to the relative specificity of these compounds in terms 
of metabolism by different CYP isoforms, and the potential for a variety of metabolic fates 
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(e.g. oxidative metabolism by CYPs, conjugation to glucuronic acid, sulfate and 
glutathione and subsequent degradation to a mercapturic acid), these compounds are 
good candidates as model substrates to assess metabolic capabilities in non-mammalian 
species. 
 
Liquid Chromatography – Mass Spectrometry (with ion fragmentation, LC-MS(MS)) has 
emerged as a sensitive tool for the detection of pharmaceuticals and their derivatives.  
This technique has been used to detect pharmaceuticals in the aquatic environment, as 
well as in waste water treatment plant discharges (Xia et al 2005, Kasprzyk-Horden et al 
2008, Palmer et al 2008).  Typically, reverse phase liquid chromatography (LC) in 
combination with mass spectrometry (MS) use combinations of water, methanol and 
acetonitrile as a mobile phase, with the inclusion of mobile phase modifiers such as 
ammonium acetate, formic acid or acetic acid to improve chromatographic separation of 
the analytes (Korfmacher 2005). Ionisation of the column eluent is achieved using a 
combination of high voltage and heat at atmospheric pressure, with electrospray 
ionisation (ESI) utilizing the nebulisation of the eluent by high voltage resulting in the 
production of aerosol particles that allow individual ions to enter the mass spectrometer 
system (ion evaporation, Korfmacher 2005).  There is a wide variety of different mass 
analysers available for application towards identifying pharmaceutical residues, including 
time of flight, quadropole and ion-trap instruments (Lim and Lord 2002).  The use of 
multiple levels of ion fragmentation (MSN) can be beneficial to the identification of 
pharmaceutical residues, where a precursor ion is fragmented into a variety of daughter 
ions which can be detected, and the process can be repeated multiple times, providing 
structural information for the precursor ions (Ermer and Vogel 2000). 
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CYP2C8/9CYP2C8/9
Ibuprofen
Ibuprofen Glucuronide
Carboxy-ibuprofen
Hydroxy-ibuprofen
Carboxy-ibuprofen Glucuronide Hydroxy-ibuprofen Glucuronide
 
Figure 4.1.  The metabolism of ibuprofen in mammals.  Oxidative metabolism of ibuprofen 
to hydroxy-ibuprofen and carboxy-ibuprofen is mediated by CYP2C8/9.  Conjugation of 
these metabolites, as well as ibuprofen, to glucuronic acid moieties also occurs. 
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SULTUGT
CYP2E1 and CYP3A4
CYP2A6
NPBQI
 
Figure 4.2.  The metabolism of acetaminophen in mammals.  The pathways of 
conjugative metabolism via the addition of sulfate or glucuronic acid moieties, as well 
oxidative metabolism, via cytochrome P450 isoforms, are represented.  The formation of 
glutathione conjugates is also shown.  These glutathione conjugates can undergo further 
metabolism to form mercapturic acid derivatives.  UGT – UDP-glucuronosyl transferases.  
SULT – Sulfotransferases.  NPBQI - N-acetyl-p-benzoquinoneimine. 
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In addition to this, the application of high resolution accurate ion mass measurements of 
both parent and daughter ions can allow the determination of the chemical composition of 
these species (Lim et al 2007).   
In order to characterise further the extent of xenobiotic metabolism that occurs in 
zebrafish larvae (96 hpf) LC-MS(MS) and scintillation counting are used as sensitive 
methods of detecting and identifying derivatives of the NSAIDs acetaminophen and 
ibuprofen, selected due to the relative substrate specificities of these compounds for 
specific CYP isoforms, and range of potential metabolic fates.  Due to limited access time 
on the machinery, the analysis of acetaminophen-exposed samples was assessed by LC-
MS only. 
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4.2 Methods 
To assess the incorporation of 14C-ibuprofen zebrafish larvae (72 hpf, 10 larvae per 
replicate) were exposed to 100 µg/l of 14C-ibuprofen or an ethanol solvent control for 0, 3, 
6, 9, 12, 18 or 24 hours at 28 ± 1°C.  These fish were then extracted by manual disruption 
between microscope slides coated in scintillation fluid, and collected in a microcentrifuge 
tube with scintillation fluid and Triton-X-100 added.  These samples were incubated at 
room temperature overnight, before assessment by scintillation counting.  For the 
assessment for ibuprofen metabolism using LC-MS(MS) zebrafish larvae (72 hpf, 100 per 
replicate) were exposed to 100 µg/l of ibuprofen, or 14C-ibuprofen, or an ethanol solvent 
control (0.0015% v/v) for 24 hours.  These samples were then extracted in 
dichloromethane, the solvent evaporated, and samples re-suspended in methanol:acetic 
acid:water.  Water samples were also retained for analysis.  These samples were then 
analysed by LC-MS(MS) as detailed in chapter 2.  Fractions (1 minute fractions) from the 
LC separated fractions of 14C-ibuprofen exposed samples (and solvent control samples) 
were collected and assessed by scintillation counting.  To determine the extent of 
conjugation of ibuprofen and its metabolites, zebrafish larvae were exposed to 14C-
ibuprofen (100 µg/l, 72 hpf larvae, 15 larvae per replicate, n=3 per treatment) or ethanol 
(solvent control) for 24 hours, followed by the homogenisation of the larvae in 25 mM 
sodium acetate (pH 4.5) buffer.  Samples were incubated at 37°C for 2 hours after the 
addition of β-glucuronidase/arylsulfatase (diluted 2664-fold) or no addition of enzyme mix 
to the samples.  All larval homogenates and water samples were then extracted three 
times with dichloromethane, evaporated to dryness, and re-suspended in sterile water.  
Scintilation fluid was then added to the samples, which were then assessed for 
radioactivity.  Both polar and non-polar fractions of the dichloromethane extractions were 
assessed by scintillation counting. 
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4.3 Results 
4.3.1 Assessment of acetaminophen metabolism by zebrafish larvae 
Zebrafish larvae were determined to have been exposed to nominal concentrations of 60 
µg/l and 500 µg/l of acetaminophen respectively.  An ion of m/z 152 and retention time 3.4 
minutes (corresponding to acetaminophen) was identified in the water samples at all time-
points and exposures sampled.  No other acetaminophen derivatives were observed in 
the water samples.  In larval extracts (500 µg/l, 24 hours exposure), an ion of m/z 230 
(retention time 2.5 minutes) was detected.  This ion was identified as acetaminophen 
sulfate based upon the m/z ratio and the comparison of the retention time of the ion with 
that of an analytical standard (Figure 4.3A and B).  Two other ions of note were identified 
in larval extracts after 24 hours exposure at both concentrations used (m/z 455 and m/z 
457, retention time 3.5 minutes, Figure 4.3C).  These ions were tentatively identified as 
the negative and positive ion forms of the acetaminophen glutathione conjugate.  Due to 
the lack of availability of an analytical standard it was not possible to use retention time to 
help identify these ions more thoroughly.  Neither of the identified ions was observed in 
larval extracts or water samples from the solvent only exposures.  
 
4.3.2 Larval uptake of 14C-ibuprofen  
Over a 24 hour time-course there was a steady increase in the incorporation of 14C 
measured in the zebrafish larval extracts exposed to 100 µg 14C-ibuprofen/l (500 nM, 
Figure 4.4). Although only approximately 2.5% of the total ibuprofen administered to the 
water was incorporated into the larvae by 24 hours, this measurement does not include 
any material that is uptaken, metabolised and excreted by the larvae.  Water samples 
from each time-point throughout the time-course did not show any significant changes in 
the 14C present in these samples, however, the qualitative context did change (see 
below). 
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Figure 4.3:  The metabolism of acetaminophen by zebrafish larvae assessed by LC-MS.  
An analytical standard for acetaminophen sulfate (A) was detected at m/z 230.  An ion of 
corresponding m/z and retention time was identified in larval extracts (B).  An ion of m/z 
455 was also detected (C) and identified as acetaminophen glutathione. 
 
A 
B 
C 
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Figure 4.4:  Mean ± standard error of the mean % of the total dose of 14C-ibuprofen 
incorporated into zebrafish larvae exposed to 100 µg 14C ibuprofen/l, over a 24 hour 
period.   (n = 3 replicates, each containing 10 larvae).   
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Table 4.1:  The m/z ratio measured by LC-MS(MS) for acetaminophen, ibuprofen and the 
metabolites of these compounds 
Putative identity Theoretical m/z Measured m/z 
Acetaminophen 
 
152.06 152 
Acetaminophen sulfate 
 
230.02 230 
Acetaminophen Glutathione 
 
455.13 455 
 
 
Putative identity Theoretical m/z Measured m/z 
Ibuprofen 205.12340 205.12427 (larval extracts) 205.12447 (water samples) 
Ibuprofen 161.13357 161.13429 (larval extracts) 161.13455 (water samples) 
Hydroxy-ibuprofen 221.11832 221.11906 (larval extracts) 221.11932 (water samples) 
Hydroxy-ibuprofen 177.12948 177.12946 (larval extracts) 177.12956 (water samples) 
14C-Ibuprofen 
 
207.12 207 
14C-Ibuprofen 
 
161.13 161 
14C-Hydroxy-
ibuprofen 
 
223.12 223 
14C-Hydroxy-
ibuprofen 
 
177.13 177 
 
The m/z ratios assessed for (A) acetaminophen and (B) ibuprofen, including the m/z ratio for 
the metabolites of each parent compound identified in this study.  Where appropriate, the 
accurate m/z ratio is given.  Otherwise the m/z ratio used to detect the ion is given. 
 
 
 
 
 
A) 
B) 
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4.3.3 Assessment of larval extracts for ibuprofen metabolites using LC-MS 
Using an analytical standard for ibuprofen sodium salt the protocol described in the 
methods section (Chapter 2, section 2.12) was optimised.  Detection of a MSMS transition 
m/z 205 → 161 corresponded to a loss of m/z 44, which was attributed to the loss of 
carbon dioxide.  The use of accurate ion mass determination was used to confirm the 
empirical formulae of both parent (m/z 205) and fragment (m/z 161) ions.  Following 
exposure to 100 µg ibuprofen/l for 6 hours no metabolites of ibuprofen were detected.  
Ibuprofen was detected in larval extracts after six hours exposure (100 µg/l) by LC-
MS(MS) and accurate ion mass determination (retention time 5.3 minutes).  After 24 
hours exposure to 100 µg ibuprofen/l, hydroxy-ibuprofen was identified in larval extracts 
(retention time 4.0 minutes, Figure 4.5).  This identification was based upon the detection 
of parent (m/z 221) and fragment (m/z 177) ions, corresponding to a loss of m/z 44 (as 
observed for ibuprofen, attributed to the loss of carbon dioxide).  The accurate ion mass 
determination for both parent and fragment ions of the identified hydroxy-ibuprofen 
confirmed the empirical formulae of both these ions.  No other metabolites were identified 
in the larval extracts. 
The use of 14C-ibuprofen as a standard resulted in identification of 14C-ibuprofen based on 
a MSMS transition of m/z 207 → 161, corresponding to a loss of 46, which was attributed 
to a loss of 14CO2.  Hydroxy-ibuprofen was identified after 24 hours exposure to 100 µg 
14C-ibuprofen/l (retention time 4.2 minutes), with this identification based upon the 
detection of a MSMS transition m/z 223 → 177 (Figure 4.6), in agreement with the 
detection of a radio-trace signal (retention time = 4.2 minutes).  No other metabolites of 
ibuprofen were observed in these samples, although ibuprofen was identified in these 
samples based upon an MSMS transition m/z 207 → 161 (loss of m/z 46, retention time 
5.7 minutes).  Both parent compound and the hydroxy-ibuprofen metabolite were 
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quantified using scintillation counting of fractions separated by the LC method used in the 
LC-MS analysis (Table 4.1).   
 
4.3.4 Assessment of water samples for ibuprofen metabolites using LC-MS 
Ibuprofen was identified in water samples after both 6 and 24 hours exposure to 100 µg 
ibuprofen/l.  Hydroxy-ibuprofen was also detected only after 24 hours exposure (retention 
time = 4.0 minutes), with this identification based upon the detection of parent and 
fragment ions (m/z 221 → 177) and confirmation of the empirical formulae of both these 
ions by accurate ion mass determination.  No other metabolites were identified in the 
water samples (Figure 4.7). 
After exposure to 100 µg 14C-ibuprofen/l (24 hours) hydroxy-ibuprofen was identified 
based on retention time (4.2 minutes) and MSMS fragmentation (m/z 223 → 177).  A 
second potential hydroxy-ibuprofen metabolite was also observed based upon this 
fragmentation transition that was not present in the solvent control or larval extracts 
(retention time = 5.6 minutes, Figure 4.8).  This second metabolite co-eluted with 
ibuprofen, thus it was not possible to use radio-trace or scintillation counting to assess if 
this metabolite contained 14C.  The amount of hydroxy-ibuprofen present in water samples 
was quantified by scintillation counting of fractions separated by LC (Table 4.1).  
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Figure 4.5:  Identification of hydroxy-ibuprofen in larval extracts, from fish exposed to 100 
µg ibuprofen/l for 24 hours.  Identification of parent ion (m/z 221, A), fragment ion (m/z 
177, B) and accurate ion mass determinations for both ions (C) used to identify hydroxy-
ibuprofen.  
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Figure 4.6:  The detection of 14C-hydroxy-ibuprofen using LC-MS(MS) in larval extracts 
from 24 hours exposure to 100 µg 14C-ibuprofen /l.  The hydroxy-ibuprofen metabolite was 
identified based upon radio-trace (A) and detection of MSMS transition 223 → 177 (C).  
Panel B shows the detection of 14C-ibuprofen in larval extracts using MSMS transition 207 
→ 161.   Panels B and C measured as relative abundance. 
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Table 4.2:  Quantification of ibuprofen and hydroxy-ibuprofen in water samples and larval 
extracts.     
Sample 1 2 3 Mean 
Standard 
error of 
the mean 
Water samples         
Ibuprofen (nmoles) 29.1 39.3 39.9 36.1 3.50 
(% of total) 75.9 99.9 98.6 91.7 
Hydroxy-ibuprofen 
(nmoles) 9.2 0 0.5 3.2 
2.99 
(% of total) 23.9 0 1.3 8.2 
Ratio of Hydroxy-
ibuprofen: ibuprofen 
0.32 0.00 0.01 0.09 0.10 
% 31.62 0.00 1.25 8.86 10.34 
Larval extracts           
Ibuprofen (pmoles) 9.5 9.5 10.1 9.7 0.20 
(% of total) 0.03 0.02 0.03 0.03 
Hydroxy-ibuprofen 
(pmoles) 44.4 27.9 26.6 32.9 
5.73 
(% of total) 0.12 0.07 0.07 0.08 
Unknown Metabolite 
(pmoles) 6.3 3.8 3.2 4.4 0.95 
(% of total) 0.02 0.01 0.01 0.01 0.00 
Ratio of Hydroxy-
ibuprofen: ibuprofen 
4.67 2.94 2.63 3.39 0.64 
% 467.37 293.68 263.37 339.18 63.55 
Ratio of unknown 
metabolite: ibuprofen 
0.66 0.40 0.32 0.45 0.10 
% 66.32 40.00 31.68 45.36 10.44 
 
Quantification of ibuprofen derivatives identified in zebrafish larval extracts and water 
samples by LC-MS and scintillation counting.  One hundred pooled larvae were used per 
replicate, with 100 µg/l of 14C-ibuprofen added to the water.  Larvae were extracted using 
dichloromethane and water samples retained after 24 hours exposure to the radiolabelled 
ibuprofen.   
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4.3.5 Assessment of ibuprofen metabolites in larval extracts and water samples using 
scintillation counting of LC fractions 
The larval extracts and water samples from the 14C-ibuprofen exposures were separated 
into fractions using the LC method from the LC-MS(MS) procedure, with each fraction 
analysed using scintillation counting for the presence of 14C.  There was no detection of 
radioactivity in either larval extracts or water samples from the solvent controls.  For larval 
extracts there were significant peaks of 14C detected in fractions 2 to 3 minutes, 3 to 4 
minutes, 4 to 5 minutes and 5 to 6 minutes (p < 0.05 Mann-Whitney U test, Figure 4.9A).  
The 3 to 4 and 4 to 5 minutes fractions were attributed to hydroxy-ibuprofen (as this peak 
elutes at approximately 4 minutes and can therefore result in signals in both 3 to 4 and 4 
to 5 minute fractions) and the peak in the 5 to 6 minute fraction has been attributed to the 
parent compound ibuprofen based upon the retention time from LC-MS(MS) experiments 
(Retention Time = 5.6 minutes).  The peak identified at 2 to 3 minutes could not be 
identified based upon LC-MS(MS) experiments.  The water sample fractions had 
detectable peaks in fractions 3 to 4 minutes and 5 to 6 minutes respectively (Figure 4.9b).  
These peaks were assigned to hydroxy-ibuprofen (3 to 4 minutes) and ibuprofen (5 to 6 
minutes) based upon retention times.  It should be noted that the peak in 3 to 4 minutes 
fraction is not statistically significantly different from the solvent control (p > 0.05, Mann-
Whitney U test), whereas the peak corresponding to ibuprofen (fraction 5 to 6 minutes) is 
statistically significant (p < 0.05, Mann-Whitney U test).  
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Figure 4.7:  Identification of hydroxy-ibuprofen in water samples, from exposures to 100 
µg ibuprofen/l for 24 hours.  Identification of parent ion (m/z 221, A), fragment ion (m/z 
177, B) and accurate ion mass determinations for both ions (C) used to identify hydroxy-
ibuprofen.  
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Figure 4.8:  The detection of two hydroxy-ibuprofen metabolites in water samples 
following exposure of zebrafish to 100 µg 14C-ibuprofen/l for 24 hours).  Panels A and B 
show the 14C radio-trace and the detection of ibuprofen.  Panel C shows two peaks 
(retention time = 4.19 and 5.56 respectively) with a MSMS transition of 223 → 177.  The 
peak at retention time = 4.19 minutes corresponds to the hydroxy-ibuprofen metabolite 
identified in larval extracts.  Panels B and C measured as relative abundance. 
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Figure 4.9:  Scintillation counting of larval extracts and water sample fractions from 24 
hours exposure (100 µg/l).  Water samples (A) and larval extracts (B) were fractionated 
using the LC settings from the LC-MS(MS) method. * indicates p<0.05. 
A 
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* 
* 
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4.3.6 Assessment of conjugation by scintillation counting 
It was determined that the recovery of radioactivity in dichloromethane extracts (non-polar 
fractions) of larval homogenates and water samples incubated with sodium acetate buffer 
only or buffer with β-glucuronidase/arylsulphatase added was approximately 86% of the 
total detected radioactivity in both polar and non-polar fractions of these samples.  There 
was no significant difference between the amount of radioactivity detected in either larval 
extracts with or without β-glucuronidase/arylsulphatase incubation or water samples with 
β-glucuronidase/arylsulphatase (p>0.05, Figure 4.10 A and B). 
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Figure 4.10.  The scintillation counting of water samples (A) and larval homogenates (B) 
extracted with dichloromethane after incubation with β-glucuronidase or buffer.  Recovery 
of radioactivity was assessed by scintillation counting.  Mean values (n=3) ± SEM are 
shown.  Relative % of total radioactivity was 92% in the water fractions and 8% in the 
larval homogenates. 
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4.4 Discussion 
To further assess the potential for xenobiotic metabolism in zebrafish larvae, we have 
exposed larvae to two model pharmaceuticals, acetaminophen and ibuprofen, and 
searched for derivatives of these compounds known from mammalian systems using LC-
MS(MS).  The aim of this work was to identify metabolites that demonstrate a wide variety 
of metabolic processes.  Evidence is provided here that suggests that zebrafish larvae 
have the ability to metabolise the NSAID acetaminophen and ibuprofen via oxidative and 
conjugative pathways.  To our knowledge this is the first study to assess the metabolism 
of pharmaceutical compounds in zebrafish larvae.   
 
In mammalian systems, acetaminophen can undergo direct conjugation to both glucuronic 
acid and sulfate moieties, in addition to cytochrome P450 mediated metabolism followed 
by glutathione conjugation and degradation to a mecapturic acid derivative (Black 1984).  
A metabolite identified as acetaminophen sulfate (based upon m/z ratio and comparison 
of retention time with that of an analytical standard) was detected in larval extracts after 
24 hours exposure (500 µg/l).  It was not possible to assess the concentration of 
acetaminophen glucuronide conjugates in this study due to a lack of sensitivity for this 
metabolite.  Direct infusion of an analytical standard of acetaminophen glucuronide 
demonstrated that this particular derivative does not ionise well, and is therefore not 
amenable to MS detection.  A metabolite identified as acetaminophen glutathione (based 
upon m/z ratio of both positive and negative ions) was also observed after 24 hours 
exposure to acetaminophen (60 µg/l and 500 µg/l).  The identification of the 
acetaminophen glutathione conjugate is supported by the detection of both positive and 
negative ion forms of this metabolite, and that these ions were not identified in the solvent 
control samples and therefore related to the exposure to acetaminophen.  The tentative 
identification of a glutathione conjugate of acetaminophen is particularly interesting, as the 
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formation of this metabolite in mammalian systems is not only indicative of CYP-mediated 
metabolism, but is also the mechanism responsible for the detoxification of the active 
metabolite of acetaminophen (Black 1984).  Thus the identification of this metabolite 
implies that zebrafish larvae can activate acetaminophen to a toxic species, known to be 
the causative agent of the associated hepatic toxicity of acetaminophen (Black 1984).  
The metabolism of the broad-specificity glutathione-S-transferase substrate 1-chloro-2,4-
dinitrobenzene has been detected throughout zebrafish development, with significant 
increases in activity post-hatching, demonstrating that zebrafish larvae have the potential 
for glutathione conjugation (Weigand et al 2000).  Indeed, a glutathione conjugate of the 
herbicide atrazine has been identified in enzyme extracts from zebrafish embryos (25 
hpf), based upon m/z ratio of the conjugate only (Weigand et al 2001).  Overall, the 
assessment of acetaminophen metabolism by zebrafish larvae suggests the presence of 
both oxidative and conjugative metabolism, including evidence for reactive intermediate 
formation. 
 
The metabolism of ibuprofen by zebrafish larvae is considerably more characterised than 
that of acetaminophen in this study.  The application of radiolabelled ibuprofen has 
allowed assessment of compound uptake and quantification of its derivatives by 
scintillation counting, combined with compound identification using LC-MS combined with 
the fragmentation of ions and accurate ion mass determination where possible.  In 
mammals, ibuprofen can be oxidised to hydroxy-ibuprofen or carboxy-ibuprofen in a 
CYP2C8/9-dependent manner (Hamman et al 1997).  The parent compound, as well as 
the metabolites, can also undergo glucuronidation (Kepp et al 1997).  Ibuprofen was 
demonstrated to accumulate steadily over 24 hours exposure in zebrafish larvae by 
scintillation counting, although the majority of the radioactivity was  detected in the water 
samples.  Analysis of the water samples and larval extracts identified both the ibuprofen 
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(m/z 205 → 161, retention time 5.3 minutes) and hydroxy-ibuprofen (m/z 221 → 177, 
retention time 4.0 minutes) in both fractions after 24 hours exposure to 12C-ibuprofen.  
Accurate ion mass determination was used to confirm the empirical formulae of the parent 
and fragment ions for both metabolites.    
 
Analysis of water samples and larval extracts exposed to 14C-ibuprofen also identified 
ibuprofen m/z 207 → 161, retention time 5.7 minutes) and the hydroxy-derivative (m/z 223 
→ 177, retention time 4.2 minutes) in both water samples and larval extracts, and an 
additional hydroxy-ibuprofen derivative in the water samples (m/z 221 → 177, retention 
time 5.7 minutes).  The detection of hydroxy-ibuprofen in the larval extracts was 
confirmed by the detection of a radio-trace signal of comparable retention time to that of 
the parent ion and fragment ion peaks (4.2 minutes).  The second identified hydroxy-
ibuprofen derivative detected in the water samples could not be confirmed using radio-
detection as the retention time for this ion was the same as that for ibuprofen (5.7 
minutes).  It is possible that this second hydroxy-ibuprofen could be a different isomer to 
the other detected metabolite, as it has been reported that such isomers can be 
separated by LC-MS (Quintana et al 2005).  All identified metabolites were quantified by 
scintillation counting of fractions (1 minute per fraction) collected from the LC of water 
samples and larval extracts.  The analysis of these fractions also detected an unidentified 
metabolite in larval extracts that had not been observed using LC-MS(MS) (retention time 
2 – 3 minutes).  The quantification of these samples showed that in the water samples the 
majority of the ibuprofen is in the parent compound form, with a small percentage (8.2%) 
detected as hydroxy-ibuprofen, with considerable variation observed in the amount of 
hydroxy-ibuprofen detected between individual replicates.  It is not known what may have 
caused this variability between the water samples.  However, in larval extracts the 
majority of the detected ibuprofen is found as metabolites, predominantly hydroxy-
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ibuprofen (3.39 times the amount of ibuprofen detected in larval extracts), with the 
unknown metabolite being a minor derivative of the parent compound (0.45 times the 
amount of ibuprofen detected in larval extracts).  Although the overall amount of 
radioactivity in the larval extracts is substantially lower than that detected in the water 
samples, there is less variability between the replicates for all the derivatives quantified in 
these samples. 
Taken together, these data show that zebrafish larvae can accumulate ibuprofen and 
metabolise it to a variety of derivatives, which can then be excreted.  The identification of 
hydroxy-ibuprofen in both larval extracts and water samples suggests that zebrafish 
possess an analogous metabolic system to the mammalian CYP2C8/9 isoforms.  
Although there is currently no orthologous gene or enzyme with similar substrate 
specificities to mammalian CYP2C8/9 identified in zebrafish, there has been a large 
number of CYP2-family genes identified, and the demonstration of an enzyme activity 
towards ibuprofen supports the hypothesis that zebrafish larvae possess similar drug 
metabolism system to that observed in mammals.  Ibuprofen has been reported to inhibit 
laurate hydroxylase activities in carp (Cyprinus carpio) liver microsomes, corresponding to 
CYP2K and CYP2M activities, suggesting that these families of enzymes may be involved 
in the oxidation of ibuprofen (Thibaut et al 2006). 
Using the LC-MS(MS) approach to metabolite identification did not provide any evidence 
to suggest that ibuprofen and its derivatives undergo conjugation in zebrafish larvae.  
However, this could be due to the use of dichloromethane as an extraction solvent for 
larval preparations, as it has been observed that dichloromethane is not suitable for the 
extraction of polar conjugates of steroids (Marwah et al 2001).  The comparison of both 
larval homogenates and water samples incubated with or without a β-
glucuronidase/arylsulphatase mix did not alter the detection of 14C signals in 
dichloromethane extracts of these preparations, suggesting that there is no significant 
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conjugation of ibuprofen by zebrafish larvae.  Although the evidence suggests that no 
appreciable conjugation occurs using ibuprofen as a substrate, we cannot exclude the 
possibility that the deconjugation of excreted metabolites can occur.  It should be noted 
that the evidence provided by this study does not mean that these conjugation systems 
are absent or not functional in larvae, as zebrafish larvae have been demonstrated in 
Chapter 3 to significantly conjugate xenobiotics such as resorufin and 7-hydroxy-coumarin 
in vivo, and adult zebrafish homogenates have been shown to both glucuronidate and 
sulfate bisphenol A (Linholst et al 2003).  Ibuprofen has also been reported to interfere 
with the glucuronidation of α-naphthol in carp (Cyprinus carpio) liver subcellular fractions, 
suggesting that fish species may be capable of conjugating ibuprofen (Thibaut et al 2006).  
In addition to this, the identification of a acetaminophen sulfate metabolite in this study 
provides further evidence of active conjugative metabolism in zebrafish larvae.  The 
glucuronide conjugates of ibuprofen, hydroxy-ibuprofen and carboxy-ibuprofen are major 
metabolites of ibuprofen excreted by mammals (Kepp et al 1997). The identification of 
hydroxy-ibuprofen in both larval extracts and water samples, in addition to the lack of 
significant glucuronidation observed, suggests that hydroxy-ibuprofen is water-soluble 
enough to be excreted without prior conjugation by zebrafish larvae, highlighting a 
species difference between mammals and zebrafish.   
The hydroxylation of ibuprofen results in the inactivation of the pharmacological activity of 
ibuprofen in mammals (Al-Nasser 2000), and thus suggests that zebrafish larvae have the 
potential to alter the pharmacology of ibuprofen via oxidative metabolism.  The observed 
sulfation of acetaminophen also provides evidence that zebrafish larvae can modulate the 
pharmacology of xenobiotics, as this process is known to inactivate acetaminophen (Fura 
et al 2004).  Ibuprofen has been detected in surface waters worldwide at a wide range of 
concentrations, ranging from low ng/l to low µg/l concentrations (Chen et al 2008).  In 
waste water treatment plant effluents in the Hudson basin (New York, USA), ibuprofen 
has been detected at concentrations ranging from <100 ng/l to >10 µg/l (Palmer et al 
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2008).  Acetaminophen is also detected in surface waters at concentrations ≤10 µg/l in 
the United States of America (Heberer 2002).  The concentrations of ibuprofen and 
acetaminophen used in this study are 10 times (ibuprofen), 6 times and 50 times the 
highest detected environmental concentrations, in order to increase the chance of 
detecting any metabolites of these compounds.  As it has been demonstrated that 
zebrafish larvae are capable of metabolising both pharmaceuticals to pharmacologically 
inactive species, as well as potentially activating acetaminophen to a toxic species 
(followed by glutathione conjugation) it is suggested that the pharmacological impacts of 
ibuprofen and acetaminophen can be limited in fish by metabolism, and that there is also 
the potential for toxic activation of these pharmaceuticals.   
 
Overall, this study demonstrates that zebrafish larvae can metabolise the NSAIDs 
acetaminophen and ibuprofen via oxidative and conjugative mechanisms.  The 
hydroxylation of ibuprofen demonstrates the presence of an othologous activity to the 
mammalian CYP2C8/9 isoform, and the sulfation of acetaminophen has also been 
demonstrated.  It is also suggested that zebrafish larvae are able to conjugate 
acetaminophen to glutathione, a process requiring CYP-dependent oxidation before 
conjugation, supporting the observation that zebrafish embryos can conjugate atrazine to 
glutathione (Weigand et al 2001).  This provides compelling evidence that these 
organisms are well suited for use in toxicity testing and front loaded drug screens.  In 
addition to this, it suggests that there is the potential for the metabolism of NSAID by 
larval fish in an environmental setting, and therefore modulation of the pharmacological 
impact of such compounds in fish species. 
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Chapter 5 
The modulation of CYP1A and EROD activity by the 
organic solvents dimethyl sulfoxide and methanol 
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5.1 Introduction 
Organic solvents are used regularly to solubilise lipophilic compounds, such as 
pharmaceuticals for use in drug metabolism studies and toxicity testing.  It was observed 
in Chapter 3 that methanol (a commonly used organic solvent, 500 µl/l) significantly 
repressed CYP and UGT1A1 gene expression and EROD activity after 24 hours exposure 
compared to unexposed larvae.  The OECD guidelines for the testing of chemicals, the 
fish screening assay for endocrine active substances (2008), recommends the use of 
minimal solvent concentrations where possible, with 100 µl/L (0.01% v/v) of solvent 
suggested as a maximum concentration, along with the use of an appropriate solvent 
control.  A major reason for minimising organic solvent concentrations in these types of 
toxicity tests is that solvents can often have toxic effects upon the test organisms, and 
thus influence the interpretation of such tests (Hallare et al 2006, Hutchinson et al 2006).  
However, the implications of solvent effects upon potential xenobiotic metabolism has not 
been previously explored in fish larvae. 
The application of zebrafish larvae to toxicity screening has resulted in the routine use of 
solvent concentrations up to 1% v/v, required to allow the solubilisation of test compounds 
into dilution water and thus to allow the exposure of zebrafish larvae to the test 
compounds (Berghmans et al 2008, Richards et al 2008, Winter et al 2008).   Although 
the comparison of test data with a solvent control is appropriate when considering 
potential toxic effects of organic carrier solvents, the potential for organic solvents such as 
methanol to modulate drug metabolism in zebrafish larvae could have an impact upon the 
predictivity of toxicity of test compounds, as some may require metabolic activation to 
produce a toxic effect.  Additionally, solvent controls cannot take into account the effects 
of solvent-agent interactions. 
This chapter investigates further the previously observed solvent effect of methanol upon 
drug metabolism systems in zebrafish larvae (see chapter 3).  As ethoxy-resorufin-O-
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deethylase (EROD) activity is well correlated with CYP1A activity in fish, the expression of 
CYP1A and EROD activity have been used as markers for the effects of methanol 
exposure upon CYP gene expression and activity (Whyte et al 2000).  The modulation of 
the aryl hydrocarbon receptors (AhRs), known to regulate the CYP1A gene in zebrafish, 
by methanol exposure has also been assessed in this study.  In order to determine if the 
observed solvent effects of methanol were solvent-specific, the commonly utilised organic 
solvent dimethyl sulfoxide (DMSO) was also assessed for any potential to reduce CYP1A 
and AhR expression, as well as for any inhibitory effects upon EROD activity.  DMSO was 
selected as it has also been used in our work to dissolve substrates such as ethoxy-
resorufin, ethoxy-coumarin and octyloxymethylresorufin, and CYP inhibitors such as α-
naphthoflavone and SKF525A.    
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5.2 Methods 
Zebrafish larvae (72 hpf) were exposed to Aroclor 1254 (100 µg/l, dissolved in methanol 
with a final concentration of 0.05% v/v), methanol only (0.05%, 0.01% or 0.001% v/v) or 
DMSO only (0.1% or 0.01% v/v) for 24 hours in dilution water.  The exposed fish were 
then used for RNA extraction using a Qiagen RNeasy kit (as directed by the manufacturer 
and detailed in chapter 2, section 2.3) for the assessment of gene expression by qPCR, 
or assessed using the EROD assay.  Extracted total RNA was reverse transcribed using 
superscript II (Invitrogen) and the 250 ng/µl of the synthesised cDNA was loaded per 
reaction with a PCR mastermix containing SYBR green dye (Quantace) for the 
assessment of CYP1A, CYP2J26, zgc:153269, UGT1A1, EF1α and RPl13α expression.  
PCR products were amplified using a program of step one: 95°C (3 minutes), step two: 
95°C (30 seconds), 60°C (30 seconds), 72°C (1 minute) and step three: 72°C (5 minutes) 
using a dissociation protocol.  Data was analysed using the ∆∆Ct method (Livak and 
Schmittgen 2001).  The EROD activity of zebrafish larvae was determined by incubating 
30 larvae per replicate per time-point with 8 µM ethoxy-resorufin and 10 µM dicumarol for 
up to 10 hours at 28°C.  To 750 µl of assay medium, 250 µl diluted β-
glucuronidase/arysulfatase was added (666- fold in sodium acetate buffer – 100 mM, pH 
4.5), and this mixture was incubated for 2 hours at 37°C.   Ethanol (100%, 1 ml) was 
added to the mixture in a fluorescence curvette, and fluorescence was measured at λex 
530 nm, λem 590 nm.  
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5.3 Results 
5.3.1 The effect of methanol upon CYP and UGT gene expression in zebrafish larvae 
Methanol (0.05% v/v, 24 hours exposure) significantly reduced the expression of CYP1A 
(to 6% of untreated levels, p<0.05, Mann-Whitney U test), the CYP-gene zgc:153269 
(CYP3A, 34% of untreated levels, p<0.05, Mann-Whitney U test), and UGT1A1 (21% of 
untreated levels, p<0.05, Mann Whitney U test), but not the expression of CYP2J26, 
compared to the level of gene expression in untreated larvae (96 hpf, Figure 5.1).  In 
order to determine if the down-regulation of the assessed genes was due to non-specific 
repression of gene expression, the effect of methanol pre-treatment (0.05% v/v, 24 hours) 
upon the expression of the validated “housekeeping” genes elongation factor 1α (EF1α) 
and ribosomal protein l13α (RPl13α) was also assessed.  Methanol pre-treatment 
significantly induced EF1α expression (5.28-fold increase compared to untreated larvae, 
p<0.05, Independent samples t-test) and did not alter the expression of RPl13α (Figure 
5.2).  Taken together, with the lack of modulation of CYP2J26, this suggests that the 
reduction in gene expression is a targeted effect of methanol treatment.  It was also 
observed that induction by co-treatment with Aroclor 1254 (100 µg/l) only partially 
compensated for the loss of expression by methanol of CYP1A (p<0.05, Mann-Whitney U 
test), the CYP-gene zgc:153269 (CYP3A, p<0.05, Mann-Whitney U test) and UGT1A1 
(P<0.05, Mann-Whitney U test, Figure 5.1).   
 
5.3.2 The effect of methanol upon CYP1A expression and EROD activity 
The expression of CYP1A in zebrafish larvae was observed to be significantly reduced by 
treatment, with 0.05% v/v methanol being highly statistically significant after 24 hours 
exposure (p<0.05, Mann-Whitney U test, Figure 5.3).  At 0.01% and 0.001% v/v, the 
reduction in expression was not significant, or significant respectively.  Methanol exposure 
at all doses significantly altered EROD activity in the live larval zebrafish assay (0.05% v/v 
  
102 
 
–p<0.05 at 2, 4, 6 and 8 hours; 0.01% v/v – p<0.05 at 2, 4, 8 and 10 hours; 0.001% v/v – 
p<0.05 at 8 hours, Figure 5.4).  Co-treatment of zebrafish larvae with Aroclor 1254 (100 
µg/l with 0.05% methanol, 24 hours) was found to recover EROD activity to near-basal 
levels (Figure 5.5).   
 
5.3.3 Assessment of the effects of DMSO on the CYP1A expression and EROD activity 
Exposure of zebrafish larvae to 0.1% v/v DMSO (24 hours) resulted in a significant 
reduction in the expression of CYP1A (p< 0.01, Independent samples t-test), whereas 
0.01% v/v DMSO did not significantly alter CYP1A expression (Figure 5.6).  There was 
only a minor inhibitory effect of DMSO observed on EROD activity at a concentration of 
0.1% v/v (p<0.05 at 6 and 8 hours), with no significant inhibition of EROD activity 
observed at a concentration of 0.01% v/v DMSO (Figure 5.7).  It should be noted that 
there the inhibitory effect of DMSO was not observed after 2 hours in the EROD assay, 
but was evident at later time-points (e.g. 6, 8 and 10 hours).  The cause of this lack of 
inhibition is unclear, but is unlikely to be due to low sensitivity of the EROD assay, as 
inhibition was observed by methanol treatment as early as the 2 hour time-point.  As 
DMSO has been used to solubilise substrates and compounds such as ethoxy-resorufin, 
α-naphthoflavone and SKF-525A throughout this work (see Chapter 3) at a concentration 
of 0.1% v/v, the effect of DMSO co-exposure upon EROD activity was assessed, with a 
slight, but not statistically significant, inhibition of EROD activity observed after 10 hours 
co-exposure to DMSO (Figure 5.8). 
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Figure 5.1:  The relative fold change in the expression of CYP and UGT1A1 genes in 
zebrafish larvae after 24 hours exposure to 0.05% v/v of methanol compared to untreated 
larvae (fold gene expression = 1).  Bars represent the mean expression of 100 pooled 
larvae (n = 3) ± SEM.  Gene expression was normalised to that of CYP2J26, as the 
expression of this gene did not change after exposure to methanol.  Statistical 
significance indicated by * (p<0.05) compared to untreated samples. 
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Figure 5.2:  The effect of methanol (0.05% v/v) exposure (24 hours) on the expression of 
the validated reference genes elongation factor 1 alpha (EF1α) and ribosomal protein l13 
alpha (RPL13α) compared to untreated larvae (relative fold expression = 1).  Bars 
represent the mean expression of 100 pooled larvae (n = 3) ± SEM.  Gene expression 
was normalised to that of CYP2J26, as the expression of this gene did not change after 
exposure to methanol.  Statistical significance indicated by ** (p<0.01) compared to 
untreated samples. 
 
 
 
 
 
** 
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Figure 5.3:  The modulation of CYP1A expression by different concentrations of methanol 
after 24 hours exposure, compared to untreated zebrafish larvae (relative fold gene 
expression = 1).  Bars represent the mean expression of 100 pooled larvae (n = 3 - 5) ± 
SEM.  Gene expression was normalised to that of CYP2J26, as the expression of this 
gene did not change after exposure to methanol.  Statistical significance indicated by * 
(p<0.05) compared to untreated samples. 
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Figure 5.4:  The effect of methanol exposure (24 hours) upon EROD activity in zebrafish 
larvae (96 hpf).  Zebrafish larvae (30 per group) were incubated for up to 10 hours with 
ethoxy-resorufin after exposure to methanol (n = 3).  Bars represent the mean pmoles of 
resorufin detected in the assay water per larva ± SEM.  Statistical significance indicated 
by * (p<0.05). 
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Figure 5.5:  The partial recovery of EROD activity in zebrafish larvae (96 hpf) by co-
exposure (24 hours) of Aroclor 1254 (100 µg/l) and methanol (0.05% v/v).  larvae (30 per 
group) were incubated for up to 10 hours with ethoxy-resorufin after exposure to methanol 
and Aroclor 1254 (n = 3).  Bars represent the mean pmoles of resorufin detected in the 
assay water per larva ± SEM.  Statistical significance indicated by * (p<0.05). 
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Figure 5.6:  The effect of DMSO exposure (24 hours) on CYP1A gene expression 
compared with untreated larvae (relative fold gene expression = 1).   Bars represent the 
mean expression of 100 pooled larvae (n = 4) ± SEM.  Gene expression was normalised 
to that of CYP2J26, as the expression of this gene did not change after exposure to 
methanol.  Statistical significance indicated by ** (p<0.01) compared to untreated 
samples. 
 
 
 
 
 
** 
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Figure 5.7:  The effect of DMSO exposure (24 hours) upon EROD activity in zebrafish 
larvae (96 hpf).  Zebrafish larvae (30 per group) were incubated for up to 10 hours with 
ethoxy-resorufin after exposure to DMSO (n = 3).  Bars represent the mean pmoles of 
resorufin detected in the assay water per larva ± SEM.  Statistical significance indicated 
by * (p<0.05). 
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Figure 5.8:  The effect of DMSO co-exposure upon the EROD activity of zebrafish larvae 
(96 hpf).  Zebrafish larvae (30 per replicate, n = 3) were incubated with ethoxyresorufin ± 
an additional 0.1% v/v DMSO.  Bars represent the mean EROD activity ± SEM.  Activity is 
expressed as the percentage of the mean EROD activity of untreated fish.  
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5.3.4 Assessment of the effects of DMSO and methanol on AhR1 and AhR2 expression 
Exposure of zebrafish larvae to 0.05% v/v methanol or 0.1% v/v DMSO had been 
observed to alter CYP1A gene expression and EROD activities. We determined if such an 
effect might be modulated by the Aryl-hydrocarbon receptors by assessing the expression 
of these regulators of CYP1A.  The exposure of zebrafish larvae to both methanol (0.05% 
v/v) and DMSO (0.1%) resulted in significantly reduced expression of both AhR1 and 
AhR2 (p<0.05 for all treatments and genes, Mann-Whitney U test, Figure 5.9) assessed 
by quantitative PCR.    
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Figure 5.9:  The effect of methanol (0.05% v/v) and DMSO (0.1% v/v) exposure (24 
hours) on the expression of aryl hydrocarbon receptors 1 and 2 in zebrafish larvae 
compared to untreated larvae (relative fold gene expression = 1).  Bars represent the 
mean expression of 100 pooled larvae (n = 4) ± SEM.  Gene expression was normalised 
to that of CYP2J26, as the expression of this gene did not change after exposure to 
methanol.  Statistical significance indicated by * (p<0.05) compared to untreated samples. 
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5.4 Discussion 
It was observed in Chapter 3 that the common organic solvent methanol had an inhibitory 
effect upon the expression of CYP and UGT genes, and also EROD activity in live 
zebrafish larvae (96 hpf).  This chapter has further investigated these inhibitory effects, 
focusing upon the CYP1A gene and EROD activity, due to the association between this 
gene and enzyme activity.  The expression of CYP1A has been assessed after exposure 
to different concentrations of methanol, as has the expression of the aryl hydrocarbon 
receptors, known regulators of CYP1A in zebrafish.  Additionally, a partial compensatory 
effect upon gene expression and EROD activity has been demonstrated using the CYP1A 
inducing agent Aroclor 1254 after exposure to methanol.  Finally, the commonly-used 
organic solvent, DMSO, has been shown to reduce the expression of CYP1A and AhR 
genes, as well as having a mild inhibitory effect upon EROD activity.  Overall, it has been 
demonstrated that organic solvents have the potential to modulate drug metabolism in 
vivo in zebrafish larvae. 
Organic solvents are widely applied throughout the life-sciences to facilitate the 
solubilisation of a variety of compounds.  It has been observed in vitro, using human liver 
microsomes, that organic solvents such as acetone, DMSO, methanol, dimethyl-
formamide (DMF) and acetonitrile can modulate CYP activities (Chauret et al 1998, 
Hickman et al 1998).  Indeed, Hickman et al (1998) reported that methanol and DMSO 
had significant inhibitory effects upon CYP1A2, CYP2C9, CYP2C19 (DMSO only) and 
CYP2E1 activities at a final solvent concentration of 1% v/v, and Chauret et al (1998) 
have observed inhibition of CYP2C8/9, CYP2C19 and CYP2E1 activity at a DMSO 
concentration of ≤0.5% v/v and CYP2C9 and CYP2E1 activities by methanol (0.5% and 
1% v/v respectively).  There are some discrepancies between these two studies, with no 
effect of DMSO or methanol exposure observed on CYP1A2 activity by Chauret et al 
(1998).  This may be attributed to the use of different marker activities for this enzyme, 
with Hickman et al (1998) using caffeine-N3-demethylation and Chauret et al (1998) using 
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phenacetin-O-deethylase activity as a marker for CYP1A2.  However, where the same 
marker activities were assessed, there was good reproducibility between the studies 
(Chauret et al 1998, Hickman et al 1998).  It should be noted that the use of microsomes 
as a model system means that induction and inhibition at the gene expression level 
cannot be assessed, and also that use of different marker substrates for a particular CYP 
isoform (for example, diclofenac-4-hydoxylase, tolbutamide-methyl-hydroxylase, 
phenytoin hydroxylase and celecoxib methyl-hydroxylase activities are all marker 
activities of CYP2C9) can provide confounding results as to the effects of solvents upon 
CYP activity (Tang et al 2000).  For example, Tang et al (2000) have reported that 
CYP2C9 activity is inhibited (celecoxib methyl-hydroxylase activity), induced (diclofenac-
4-hydoxylase and tolbutamide-methyl-hydroxylase) and not affected by exposure to 
acetonitrile, depending which marker activity is assessed.  Treatment of human 
hepatocytes with DMSO and methanol resulted in the inhibition of CYP2C9, CYP2C19, 
CYP2E1 and CYP3A4 (DMSO) and CYP2C9 and CYP2E1 (methanol) activities using 
solvent concentrations at 1% v/v or greater (Easterbrook et al 2000).  There were no 
observed effects of solvent exposure upon conjugation activities corresponding to UGT or 
SULT isoforms observed using DMSO, methanol or acetonitrile in these human 
hepatocytes (Easterbrook et al 2000).  The effect of organic solvents upon activities of 
cDNA–expressed CYP isoforms re-iterates the observations from microsomal 
incubations, that substantial inhibition of CYP activities can occur at solvent 
concentrations ≤1% v/v, and that the observed inhibitions are dependent upon the 
substrate utilised as a marker for CYP isoform activity (Busby et al 1999).  It is interesting 
to note that the majority of these studies recommend methanol as a suitable solvent for 
use in metabolism studies, and that DMSO is generally found to have the more 
substantial inhibitory profile however, this conclusion is limited as none of these studies 
assess the effect of solvents upon the gene transcription and expression.   
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The use of microsomal fractions to assess the effects of solvents upon CYP activities 
removes the potential for regulation of gene expression by these compounds.  The effects 
of DMSO exposure upon the gene expression of CYP and UGT isoforms in human 
primary hepatocytes has also been assessed after 24 hours exposure (Nishimura et al 
2003).  It was observed that DMSO concentration less than 0.5% v/v did not significantly 
alter the expression of CYP and UGT genes however, a concentration of 2.5% v/v DMSO 
did result in mild modulation (Nishimura et al 2003).  This modulation was found to be 
somewhat variable between different donors of hepatocytes, and the genes CYP1B1, 
CYP2E1 and CYP3A4 were induced by treatment (2 – 3 fold above control) whereas 
CYP3A7 and UGT1A9 were down-regulated to 0.2 – 0.5 fold of the untreated level 
(Nishimura et al 2003).  Corresponding data on activity was not reported to complement 
the gene expression data in this study.  However, comparisons with other hepatocyte 
studies (such as that by Easterbrook et al 2000) suggests that, as inhibition of activity is 
only seen at solvent concentrations of 1% v/v or greater, the regulation of gene 
expression may be part of the mechanism for organic solvent-mediated inhibition.  The 
direct inhibitory effects of solvent exposure cannot be discounted, due to the effects 
observed using microsomal preparations.       
Using zebrafish larvae, the modulation of CYP and UGT gene expression by the organic 
solvents DMSO and methanol has been demonstrated in vivo, at substantially lower 
concentrations than those applied to in vitro systems, such as cultured hepatocytes or 
microsomal fractions (0.05% v/v methanol and 0.1% DMSO compared with ≥0.5% v/v for 
both solvents respectively).  Similarly, the inhibition of EROD activity by methanol (0.05%, 
0.01% and 0.001% v/v) and DMSO (0.1% v/v) has been demonstrated using a live larval 
assay, which agrees with the reported inhibition of CYP1A1 activity in cDNA-expressing B 
lymphoblastoid cells by these solvents (measuring phenacetin-O-deethylase activity and 
using substantially higher solvent concentrations however, cDNA-expressed enzymes are 
not under the control of the AhR, and are constitutively expressed and thus do not reflect 
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any regulation of gene expression).  It should be noted that for methanol-exposed larvae, 
inhibition of EROD activity is observed at concentrations where there is no significant 
change in gene expression comparing to untreated samples (0.01% v/v).  This suggests 
that regulation of gene expression is not the complete mechanism by which solvent-
mediated inhibition of EROD activity occurs.  However, the use of the CYP gene 
expression inducing agent Aroclor 1254 does partially compensate for the reduction in 
gene expression and EROD activity upon co-exposure with methanol.  It is possible that 
the co-treatment with Aroclor 1254 is not preventing or reducing the inhibitory effects of 
methanol, but simply causes an induction in gene expression and EROD activity, thus 
masking the inhibition caused by the solvent.  The down-regulation of the CYP1A 
regulators, aryl hydrocarbon receptors 1 and 2 (AhR1 and AhR2) by DMSO and methanol 
exposures does also imply that genetic regulation of CYP genes by organic solvents is 
involved in the mechanism for producing the observed effects.  The regulation and 
network of interactions of AhR is highly extensive, and the mechanism of the observed 
solvent-mediated down-regulation is unclear (Figure 5.10).  However, DMSO is known to 
have some anti-oxidant properties and as methanol is an alcohol it can potentially have 
anti-oxidant properties (via conversion to a carboxylic acid, it is not known if this is a 
biologically-relevant mechanism), and it has been suggested, using TAKA-1 cells that 
AhR expression is down-regulated in the presence of antioxidants (Zhang et al 1998, 
Santos et al 2003).  There is also substantial interaction between the AhR and NF-E2p45-
related protein (NRF2), which is a known regulator of anti-oxidant genes and has also 
been reported to regulate AhR expression in mouse cells (Shin et al 2007).  It is thus 
possible that solvents mediate the observed down-regulation of AhR and its downstream 
effectors through interactions with NRF2.  Taken together with evidence from in vitro 
systems (such as human microsomal fractions and hepatocyte cultures), it appears that 
zebrafish larvae are sensitive to organic solvent-mediated modulation of CYP activities, 
partially regulated via alterations in gene expression (mediated via the expression of 
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nuclear receptors such as the aryl hydrocarbon receptors) and potentially via direct 
interaction with the enzymes themselves. 
 
Zebrafish larvae are currently being applied in a multi-tier approach as part of the drug 
discovery and toxicity testing paradigm.  Waterborne exposures are a common method 
for exposing zebrafish (adult and larvae) to pharmaceutical compounds, due to the rapid 
uptake of small molecules through the skin and gills by embryonic and larval zebrafish 
(McGrath and Li 2008).  It is also common for pharmaceutical compounds to be dissolved 
in organic solvents, in order to overcome solubility issues, and allow waterborne exposure 
as a route of administration in toxicity testing assays (Barros et al 2008).  Zebrafish larvae 
are tolerant to DMSO at high concentrations (up to 4%), and concentrations of 1%  are 
routinely used in drug toxicity assays (Winter et al 2008).  In view of the observed 
inhibitory effects of DMSO and methanol observed in this study, and of the apparent 
sensitivity of zebrafish larvae to solvent-mediated modulation of drug metabolism genes 
(≤0.1% v/v of solvents elicit inhibitory effects), the use of minimal solvent concentrations, 
with 0.001% v/v recommended as a maximum concentration applied to assays.  Overall, 
the data presented in this chapter, and in Chapter 3 (induction of gene expression by 
Aroclor 1254) also highlights the importance of an appropriate solvent control for use in 
drug metabolism screening in vivo using zebrafish larvae, as there is the potential for 
solvents to modulate the xenobiotic metabolism capabilities of the fish.  The implications 
of the use of solvents in zebrafish toxicity testing assays are the potential for the 
overestimation (of the toxicity of compounds that are inactivated by metabolism) or 
underestimation of toxicity (for compounds that require activation by metabolism).  There 
is also potential for the alteration of the qualitative profile of compound metabolism, 
mediated through the modulation of specific drug metabolism genes. 
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Figure 5.10:  The known interactions of the Aryl Hydrocarbon receptor (AhR) with 
endogenous and exogenous factors.  Figure was produced using the Ingenuity Pathway 
Analysis software (version 8.5, accessed December 2009). 
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6.1 General discussion 
The application of zebrafish larvae to drug safety assessment along with the identification 
of pharmaceutical residues in the aquatic environment has resulted in the requirement for 
the assessment of xenobiotic metabolism in fish species to be assessed.  As zebrafish, 
both adult and larvae, are utilised in both toxicity testing and ecotoxicology (as discussed 
in Chapter 1), there is now a focus upon characterising the complement of CYP, UGT, 
GST and SULT enzymes present throughout embryonic development and adult life 
stages.  This project has focused upon the expression of CYP and UGT genes and during 
embryonic development and larval stages, and assessed xenobiotic metabolism during 
development and post-hatching. 
Zebrafish embryos and larvae have been reported to express several CYP genes 
including CYP1A, CYP1B1, CYP1C1, CYP1D1, CYP2K6,  CYP2J1, CYP3A65 and 
CYP3C1 (Tseng et al 2005, Wang-Buhler et al 2005, Corley-Smith et al 2006, Jönsson et 
al 2007, Wang et al 2007, Goldstone et al 2009).  These genes have been reported to 
display distinct patterns of expression throughout embryonic and larval development, in 
addition to tissue-specific expression patterns.  For example, CYP1A expression 
increases steadily throughout development, whereas CYP1D1 expression is initially 
relatively high and decreases in the first 24 hours of development followed by an increase 
in expression by 3 dpf, with a slight decrease to a constant level of expression in adult 
tissues (Goldstone et al 2009).  The CYP2K6 gene has been detected in zebrafish larvae 
from 5 dpf onwards and in adult tissues, whereas CYP3A65 has been observed to 
steadily increase in expression throughout development (Tseng et al 2005, Wang-Buhler 
et al 2005).  The developmental expression profiles of SULT genes have been extensively 
characterised, with isoform-specific patterns of gene expression observed (Ohkimoto et al 
2003, Sugahara et al 2003, Liu et al 2005, Yasuda et al 2005a, Yasuda et al 2005b, 
Yasuda et al 2006, Liu et al 2008, Yasuda et al 2008).  Chapter 3 demonstrated that 
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CYP1A, CYP2J26, CYP-gene zgc:153269 (CYP3A) and UGT1A1 genes are expressed in 
distinct temporal patterns throughout development, with a general trend for increased 
expression post-hatching.  These observed patterns of expression either confirmed 
previously-reported expression (CYP1A), or are the first reported study into the 
expression of these genes throughout development (CYP2J26, the CYP-gene 
zgc:153269 and UGT1A1).  It should be noted that the expression of these genes was 
assessed in a qualitative manner, although the expression of CYP1A does agree with 
previously reported temporal patterns.  The identification of temporal patterns of 
expression during development not only suggests a role for these genes during normal 
development (as in human embryonic development xenobiotic metabolism enzymes have 
endogenous as well as exogenous substrates such as the metabolism of steroidal 
hormones (oestrogen and testosterone) and the conjugation of billirubin), but also raises 
an additional consideration in that certain stages of embryonic development may be better 
suited, in terms of xenobiotic metabolism, to toxicity testing than others (Miller et al 1996).  
The presence or lack of drug metabolism systems at different developmental stages 
suggests that there is variability in the susceptibility of developing organisms to chemical 
toxicity during development.  It is not currently clear as to why there is such variation in 
the expression of certain CYP activities throughout development however it may be linked 
to the roles of these systems in organogenesis.  It should also be noted that similar 
regulation of EROD activity has been observed in mice as seen for zebrafish, with the 
detection of CYP1A1 mRNA without EROD activity, suggesting that the delay in onset of 
certain drug metabolism activities is a conserved process in normal embryonic 
development (Mattingly and Toscano 2001).  Thus the developmental stages with the 
widest range of CYP, UGT, GST and SULT isoform expression would be expected to 
more accurately reflect the extent of toxic activation or inactivation of test compounds, 
compared to adult mammalian systems. 
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The highest levels of mRNA for the CYP isoforms identified in this study were detected 
post-hatching (at 96 hpf).  This observation, in addition to the observation of Mattingly and 
Toscano (2001), that CYP activity towards the substrate ethoxy-resorufin is only detected 
post-hatching in zebrafish larvae, resulted in the assessment of xenobiotic metabolism 
activities occurring after the larvae had hatched from the chorion.  In addition to this, 
exposures of zebrafish larvae to inducing agents, inhibitors and substrates of CYP 
enzymes only utilised hatched zebrafish larvae, in order to reduce any potential reduction 
of compound uptake or organism exposure by the chorion or perivitteline fluid.  It is 
unknown to what extent the chorion acts as a barrier to xenobiotics, and the detection of 
the toxic effects upon unhatched zebrafish larvae using chemicals such as TCDD 
suggests that it is at best a semi-permeable barrier to chemicals (Karchner et al 2005).  
However, large molecules such as fluorescein dextrans are excluded by the chorion, as 
are lipopolysaccharides (Scholz et al 2008).  It has been shown by monitoring the 
disposition of cadmium in unhatched zebrafish embryos that only a small percentage of 
the detected cadmium is associated with the actual embryo, with the majority of this 
compound associated with the chorion and the perivitteline fluid of the egg (Burnison et al 
2006).  Other considerations with regards to the absorption of xenobiotics into the embryo 
or larvae include the presence or absence of functioning gills and the extent (if any) of 
dietary exposure to xenobiotics.  Although zebrafish embryos and larvae develop rapidly, 
it is not until post-hatching that functional gills develop, and the mouth opens, allowing 
exposure via the digestive tract (Kimmel et al 1995).  Thus, the uptake of compounds 
preceding the formation of functional gills and the opening of the mouth is probably 
facilitated by processes such as diffusion, or is dependent upon the lipophilicity of the 
compound.  Overall, the processes involved in the absorption of xenobiotics are poorly 
characterised and thus substantial investigation into the processes of xenobiotic uptake 
by zebrafish embryos and larvae are required. 
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This study has used a live in vivo fluorescence-based assay system to assess the 
metabolism of ethoxy-resorufin, 7-ethoxy-coumarin and octyloxymethylresorufin to 
demonstrate activities similar to mammalian CYP1, CYP2 and CYP3 respectively.  As 
these assays require the uptake of the substrate and the excretion of the product in order 
to produce a quantifiable signal, each of these processes has been demonstrated for 
these compounds (Chapter 3).  However, it should be noted that although the substrates 
used in this study are metabolised by a variety of mammalian CYP isoforms, only a few 
examples of these oxidative and conjugative processes are presented in this work.  
Further characterisation using other broad-specificity CYP substrates (such as 
benzyloxyresorufin, methoxyresorufin and pentoxyresorufin) or by monitoring isoform-
specific reactions (for example, the 6β-hydroxylation of testosterone) is required to 
determine the extent of oxidative and conjugative systems in zebrafish embryos and 
larvae.   We have also demonstrated the uptake of acetaminophen and ibuprofen, as well 
as the excretion of metabolites of these pharmaceuticals (Chapter 4).  There are few 
examples of the metabolism of pharmaceuticals by fish species, especially at larval 
stages.  For example, the depuration of fluoxetine has been assessed in adult Japanese 
medaka (Oryzias latipes, Paterson and Metcalfe 2008).  Although the absorption, 
metabolism and excretion of characteristic substrates such as ethoxy-resorufin provides 
evidence demonstrating the presence of processes such as drug uptake and oxidative 
and conjugative metabolism, the fate of pharmaceuticals in zebrafish is of particular 
interest due to the application of zebrafish to drug discovery toxicity testing and 
ecotoxicology.  Ibuprofen was demonstrated to accumulate in zebrafish larvae over a 24-
hour period using scintillation counting.  The identification of acetaminophen derivatives in 
larval extracts also demonstrates compound uptake, and the identification of ibuprofen 
metabolites in water fractions from zebrafish exposures is evidence of excretion.  There 
are several potential routes of excretion for xenobiotic compounds and their derivatives.  
In mammals, the common routes of excretion is in urine or faeces (via the excretion of 
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compounds into the bile), with minor excretion via sweat or exhalation (Timbrell 2000).  
The drug transporter proteins such as the ATP-binding cassette (ABC) proteins, organic 
anion transporter proteins (OATP) and multi-drug resistance proteins (MDR) have a 
critical role in the excretion of xenobiotics (as well as endogenous substrates) into bile, 
and thus in excretion (Faber et al 2003).  There have been 52 identified ABC transporter 
proteins identified in the zebrafish genome, in addition to a multi-drug resistance protein 
(MDR), suggesting that these potential routes of uptake and excretion of xenobiotics are 
present in the developing zebrafish (Bresolin et al 2005, Annilo et al 2006).  It has been 
observed that the use of the ABC protein inhibitor cyclosporin A results in the 
accumulation of the fluorescent dye rhodamine red in zebrafish embryos (24 hpf), 
demonstrating the role of these proteins in the excretion of this compound (Scholz et al 
2006).   
 
Chapters 3 and 5 have demonstrated and assessed the induction and inhibition of CYP 
and UGT gene expression and activities in zebrafish larvae.  The modulation of CYP and 
UGT genes by xenobiotics has been well described in mammals, and these processes 
are mediated by a variety of nuclear receptors, including the aryl hydrocarbon receptor 
(AhR), pregnane X receptor (PXR), peroxisome proliferator-activated receptors (PPARs) 
and constitutively activated receptor (CAR, Xu et al 2005).  Unliganded AhR is 
predominantly located in the cytoplasm of cells, bound to the molecular chaperone 
heatshock protein 90 (hsp90), and upon ligand binding translocates to the nucleus, 
exchanging hsp90 for aryl-hydrocarbon receptor nuclear translocator (ARNT) in the 
process, and binds specific DNA sequences in the promoter regions of target genes 
(termed response elements, Xu et al 2005).  The orphan receptors such as PXR and 
CAR, form heterodimers with the retinoid X receptor (RXR) within the nucleus upon ligand 
binding, resulting in the modulation of gene expression (Tompkins and Wallace 2007).  
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These receptors affect the expression of a variety of stress and xenobiotic metabolism 
genes, including some (but not all) CYP, UGT, GST and SULT isoforms and drug 
transporter proteins (Waxman 1999, Xu et al 2005).  It should be noted that these nuclear 
receptors also have endogenous functions, in addition to the modulation of the 
metabolism of xenobiotics, and are involved in the maintenance of homeostasis and 
development (Bainy 2007).  These receptors also have some constitutive activities in the 
absence of ligand binding, with CAR having the highest activity in the absence of ligand 
binding (Bainy 2007).  The potential for the activation of these receptors in the early life-
stages of zebrafish means that the induction of drug metabolism systems (as well as 
other downstream targets of these nuclear receptors) by exposure to environmental 
contaminants, such as polychlorinated biphenyls and PAH, as well as exposure to 
pharmaceuticals that are ligands of these receptors can be observed and assessed in 
zebrafish larvae.   
The AhR pathway has been extensively characterised in zebrafish larvae, due to the 
involvement of this receptor in TCDD toxicity (Carney et al 2006).  There are three AhR-
family members known in zebrafish, named AhR1a, AhR1b and AhR2 respectively (Wang 
et al 1998, Tanguay et al 1999, Andreasen et al 2002).  Unlike mammals, which only have 
a single AhR gene, it is common for fish to have at least two AhR forms (AhR1 and 
AhR2), and these fish AhRs differ from mammalian forms by having longer amino acid 
sequences and a lack of a glutamine-rich region at the C-terminus of the protein 
(Andreasen et al 2002).   
 
The two identified AhR1 family members, designated AhR1a and AhR1b respectively, 
have been demonstrated to be expressed throughout zebrafish development with AhR1a 
and AhR1b expression increasing throughout development from 24 hpf onwards 
(Andreasen et al 2002, Karchner et al 2005).  The modulation of gene expression for both 
AhR1 forms by TCDD (2 nM) has also been assessed during development, with mild 
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induction AhR1a but no modulation of AhR1b.  Furthermore, the AhR1a form has been 
demonstrated to be expressed in the liver, heart, swim-bladder and kidney of adult 
zebrafish (Andreasen et al 2002).  The AhR1a isoform has been reported not to be 
functionally active using a transfected COS-7 cells (these cells are used as a model 
system due to having minimal AhR regulation) with transfected AhR and its co-activator 
ARNT2b for activation of a luciferase construct containing an AhR response element 
(Andreasen et al 2002).  Exposure to a variety of model and non-model AhR ligands, such 
as TCDD, β-naphthoflavone, benzo-[a]-pyrene and 7,12-dimethylbenz-[a]-anthracene 
resulted in the production of minimal luciferase activity (Andreasen et al 2002).  The 
AhR1b form has been shown to be active upon TCDD treatment using a similar system 
(Karchner et al 2005).  The AhR2 form has also been assessed for gene expression 
across development, with detectable expression from 24 hpf increasing through to 
maturity (Tanguay et al 1999).  There has also been detection of AhR2 expression in 
most adult tissues including heart, liver, gill, brain, kidney, swim-bladder, skin, eye and fin 
(Andreasen et al 2002).  The induction of AhR2 expression by TCDD has been 
demonstrated in both developing embryos (12 – 96 hpf) and a zebrafish liver cell line by 
Northern blotting (Tanguay et al 1999).  It has also been shown using the COS-7 cell 
transfection system that AhR2 is functionally active upon exposure to a variety of AhR 
ligands including; TCDD, β-naphthoflavone (β-NF), benzo-[a]-pyrene and 7,12-
dimethylbenz-[a]-anthracene.  Due to the availability of an AhR2-specific zebrafish 
antibody, there has also been an assessment of the protein levels and degradation of 
AhR2 in zebrafish liver cells (Wentworth et al 2004).  The degradation of AhR2 has been 
demonstrated to be mediated by ligand binding (using β-naphthoflavone as a model 
ligand) and 26S proteosome dependent, as the observed decrease in AhR2 protein levels 
after β-NF exposure is prevented by co-incubation with the proteosome inhibitor MG-132 
(Wentworth et al 2004).  The application of this antibody to immunohistochemistry has 
demonstrated that in untreated cells AhR2 localised to the nucleus and cytoplasm, with 
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increased nuclear staining upon β-NF exposure (Wentworth et al 2004).  Incubation of 
these cells with a nuclear export inhibitor reduced staining in the cytoplasm, suggesting 
that AhR2 “shuttles” between both compartments of the cell (Wentworth et al 2004).  As 
well as the different AhRs described above there have been several related factors 
including AhR interacting protein (AIP), AhR repressors (AhRr) and co-activators such as 
ARNT have all been identified in zebrafish.  The use of morpholino knockdown of the 
various different isoforms of these factors has been used to dissect the molecular 
mechanism of TCDD toxicity (Evans et al 2005, Prasch et al 2006).  
The zebrafish PXR has also been identified and demonstrated to be activated by a subset 
of the known ligands of the human PXR (Reschly et al 2007, Ekins et al 2008).  This 
limited set of ligands has been proposed to be due to a smaller ligand binding domain 
than that of the human nuclear receptor (Ekins et al 2008).  Bresolin et al (2005) have 
reported that PXR is expressed in adult zebrafish liver however, the expression and 
extent of function of PXR in embryonic and larval tissues, and throughout development 
has yet to be fully determined.  It should be noted that there is currently no identified 
zebrafish CAR, although other nuclear receptors such as peroxisome proliferator-
activated receptors (PPARs) have been identified (Bainy 2007).     
This study has primarily used ligands of the AhR such as α-naphthoflavone and Aroclor 
1254 to induce CYP and UGT gene expression and activities (Chapter 3).  These nuclear 
receptors have also been implicated as part of the mechanism for solvent-mediated 
down-regulation of CYP1A gene expression and EROD activities in zebrafish larvae by 
methanol and DMSO (Chapter 5).  The routine use of high concentrations (≥1% v/v) of 
solvents such as DMSO and methanol in zebrafish safety assessment and toxicity assays 
(e.g. those of Berghmans et al 2008, Richards et al 2008 and Winter et al 2008) may 
result in reduced correlations of predictivity (comparing to mammalian species) of these 
assays, due to altered biotransformation of the test compounds.  Thus caution should be 
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exercised when analysing such data, taking into account if the metabolism of the test 
compound either promotes toxicity, pharmacological effect, or renders the compound 
pharmacologically inactive.  The induction of CYP and UGT expression, and EROD 
activity, by Aroclor 1254 is the first demonstration of such effects of this mixture of 
polychlorinated biphenyls in zebrafish, with Troxel et al (1997) reporting that Aroclor 1254 
(using dietary exposure or intra-peritoneal injection) failed to induce CYP expression in 
adult zebrafish.  Chapter 3 surprisingly demonstrated that the CYP inhibitors α-
naphthoflavone and SKF525A induced EROD and OOMR activities, and did not inhibit 
ECOD activity in zebrafish larvae.  The induction of EROD activity by α-naphthoflavone 
has been attributed to the potential for this compound to act as a mild agonist of AhR, and 
it is suggested that SKF525A may also act as a ligand for another nuclear receptor in 
order to mediate the induction of OOMR activity.  These effects demonstrate that not only 
do zebrafish larvae express genes and activities for the metabolism of xenobiotics similar 
to those observed in mammals, but that these activities can also be modulated (induction 
and inhibition) in a manner similar to those observed using mammalian systems.  
Although there are only a few examples of such modulation in this thesis, and further 
examples are required to confirm such findings, these observations not only support the 
use of zebrafish larvae as a model system for safety assessment with regards to drug 
metabolism influencing toxicity, but as a result of the inducibility (and inhibition) of such 
systems, there is the potential to assess and identify any potential drug-drug interactions 
that a test compound may have.   
   
Another important consideration is the relevance of the work presented in this thesis to 
the field of ecotoxicology.  The identification of pharmaceuticals from a range of 
therapeutic classes in the aquatic environment has demonstrated that aquatic species are 
exposed to low concentrations of xenobiotics (Jones et al 2002, Cunningham et al 2008, 
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Farrè et al 2008).  Thus the disposition and fate of such compounds within species such 
as fish is of relevance to the consideration of the environmental safety of 
pharmaceuticals.  The demonstration of the metabolism of acetaminophen and ibuprofen 
by larval zebrafish (Chapter 4) suggests that there is potential for the conversion of 
pharmaceuticals from toxic species to non-toxic species, and vice versa, as well as the 
potential modulation of the pharmacology of compounds.  Thus the application of 
zebrafish larvae (96 hpf) to ecotoxicology toxicity testing is likely to reflect the 
biotransformation of test compounds along with any toxic effects, although further 
examples of, and confirmation of, the bioactivation of xenobiotics to toxic derivatives are 
required to strengthen this conclusion. 
The application of model organisms such small fish species including the zebrafish (and 
in particular embryonic and larval zebrafish) to toxicity testing results from a desire to 
instigate in vivo assessments of compound toxicity, and to increase the attrition of 
candidate drugs before testing in rodent and non-rodent species (i.e. if a compound is 
going to fail due to toxicity then it is best to fail in the early stages of toxicity testing).  In 
addition, the use of small fish species complies with the 3R’s directive (the reduction, 
replacement, and refinement of animal model systems) for the use of animals in scientific 
research.  In order for such model organisms to adequately fufil these roles it is important 
that similar pharmacology, metabolism, distribution and excretion of test compounds as to 
that observed in humans is reflected by the organisms.  In this thesis, it has been reported 
that zebrafish have similar oxidative (CYP enzymes) and conjugative (such as UGT and 
SULT enzymes) systems present as those found in mammalian species for the 
metabolism of xenobiotics, although continued characterisation of the metabolism of 
xenobiotics using a wider range of characteristic and pharmaceutical substrates is 
required, and thus suggests that they will be appropriate for use in drug screening and 
toxicity testing strategies.  Finally, this thesis has highlighted an apparent sensitivity of 
EROD activity and CYP gene expression to DMSO and methanol exposure.  This finding 
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may have implications upon the interpretation of toxicity testing assays using zebrafish 
larvae.   
  
6.2 Future work 
Although, as discussed above, this work strengthens the justification for the application of 
zebrafish larvae to toxicity testing, further characterisation of the metabolism of 
xenobiotics in this organism is required.  Further examples of the metabolism of 
pharmaceuticals, in addition to acetaminophen and ibuprofen, from a variety of different 
therapeutic classes are required in order to strongly compare zebrafish larvae and 
mammalian species in terms of the metabolism of xenobiotics.  The analysis of the 
metabolism of  compounds such as caffeine, coumarin, diazepam, fluoxetine, simvastatin 
and tamoxifen, using techniques such as LC-MS(MS) and/or nuclear magnetic resonance 
spectroscopy (NMR) would allow the identification of metabolites produced by specific 
enzyme isofoms (e.g. human CYP3A4 catalyses the 8-hydroxylation of caffeine, Brown et 
al 2008).  The monitoring of such reactions would not only provide examples of 
xenobiotics that are metabolised by zebrafish larvae, but would also identify enzyme 
activities similar to those found in mammals, and thus help characterise to what extent the 
similarities in substrate specificity between zebrafish and mammals exist.  An important 
consideration, with regards to toxicity, is often the balance between the “phase I” oxidative 
and reductive activities and the “phase II” conjugative activities of drug metabolism 
systems, and even between multiple different CYP isoforms for a given substrate.  As a 
result the predictivity of model organisms for human toxicity is never going to be 100% 
reliable, especially when human inter-individual variability (polymorphic variant for drug 
metabolism enzymes) is also considered.  It should be noted that this is not just an issue 
for the use of fish as a model organism, as rodent models also suffer from this limitation.  
The identification of any toxic species and pharmacologically-inactive species would also 
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provide additional evidence that zebrafish larvae can modulate the pharmacology of 
foreign compounds.  Determining the distribution of xenobiotic compounds within the 
larvae itself would also provide useful information, and could be achieved using either 
fluorescent substrates (for example, rhodamine red accumulation has been demonstrated 
by Scholz et al, 2006), or by autoradiography using radio-labelled compounds.  The 
identification of tissue expression patterns of CYP, UGT, GST and SULT genes in 
zebrafish embryos and larvae throughout development would also provide useful 
information, particularly with respect to tissue-specific toxicity.  The application of in situ 
hybridisation using DIG-labelled RNA probes specific for a wide range of xenobiotic 
metabolism genes would allow such an assessment.  In addition to the characterisation of 
the zebrafish xenobiotic metabolism systems there is also potential for the insertion of 
human drug metabolism genes (e.g. CYP3A4) into the zebrafish.  The resulting 
“humanised” zebrafish may more accurately predict potential compound toxicity than 
“non-humanised” fish, due to the presence of human enzyme activity and substrate 
specificities, as well as the zebrafish ones.  
The demonstration that the in vitro inhibitors α-naphthoflavone and SKF525A induced 
EROD and OOMR activities in zebrafish highlighted the potential for the assessment of 
drug-drug interactions in vivo using zebrafish larvae.  This approach would be of great 
benefit for drug discovery, as by monitoring specific reactions (e.g. EROD activity) it is 
possible to assess the effect of compounds upon the metabolism of others.  Processes 
such as induction and inhibition are reflected using an in vivo system such as the 
zebrafish larvae, as demonstrated in Chapters 3 and 5. 
Finally, the observed effects of the organic solvents DMSO and methanol highlight an 
area requiring further investigations.  It would be important to determine which solvent, if 
any, has the least or no modulatory effects upon zebrafish drug metabolism genes and 
activities.  Also, determining whether the observed effect is specific for EROD activity or 
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CYP activities in general would be of great benefit, as there is evidence provided in this 
study that the expression of several genes is affected upon solvent exposure.  Assessing 
the effect of solvents upon the GST and SULT isoforms would also be of great benefit.  
The identification of no-effect levels for solvents would be of great use for providing 
suitable guidelines for vehicle usage in toxicity testing using zebrafish larvae. 
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Appendix  
tr|Q6TH23|Q6TH23_DANRE           MALTILPILGPISVSESLVAIITICLVYLLMRLNRTKIPDGLQKLPGPKP 50  
gi|4503199|ref|NP_000490.1|      ---MLFPIS--MSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWG 45 
                                     ::**   :*.:* *:* : :***: ::* .*.::*.**:: ***   
 
tr|Q6TH23|Q6TH23_DANRE           LPIIGNVLEIGNNPHLSLTAMSKCYGPVFQIQIGMRPVVVLSGNDVIRQA 100 
gi|4503199|ref|NP_000490.1|      WPLIGHMLTLGKNPHLALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQA 95 
                                  *:**::* :*:****:*: **: ** *:**:**  ******* *.**** 
 
tr|Q6TH23|Q6TH23_DANRE           LLKQGEEFSGRPELYSTKFISDGKSLAFSTDQVGVWRARRKLALNALRTF 150 
gi|4503199|ref|NP_000490.1|      LVRQGDDFKGRPDLYTFTLISNGQSMSFSPDSGPVWAARRRLAQNGLKSF 145 
                                 *::**::*.***:**: .:**:*:*::**.*.  ** ***:** *.*::* 
 
tr|Q6TH23|Q6TH23_DANRE           STVQGKSPKYSCALEEHISNEGLYLVQRLHSVMKADGSFDPFRHIVVSVA 200 
gi|4503199|ref|NP_000490.1|      SIASDPASSTSCYLEEHVSKEAEVLISTLQELMAGPGHFNPYRYVVVSVT 195 
                                 * ... :.. ** ****:*:*.  *:. *:.:* . * *:*:*::****: 
 
tr|Q6TH23|Q6TH23_DANRE           NVICGICFGRRHSHDDDELVRLVNMSDEFGKIVGSGNPADFIPFLRILPS 250 
gi|4503199|ref|NP_000490.1|      NVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPILRYLPN 245 
                                 ****.******:.*:.:**: ***:.::**::***********:** **. 
 
tr|Q6TH23|Q6TH23_DANRE           TTMKKFLDINERFSKFMKRLVMEHYDTFDKDNIRDITDSLINHCEDRKLD 300 
gi|4503199|ref|NP_000490.1|      PSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLD 295 
                                 .::: * *:**:* .**:::* ***.**:*.:*********:**::::** 
 
tr|Q6TH23|Q6TH23_DANRE           ENSNLQVSDEKIVGIVNDLFGAGFDTISTALSWAVVYLVHYPEVQERLQR 350 
gi|4503199|ref|NP_000490.1|      ENANVQLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQE 345 
                                 **:*:*:*****:.** *********::**:**:::***  *.**.::*. 
 
tr|Q6TH23|Q6TH23_DANRE           ELDEKIGKDRTPLLSDRANLPLLESFILEIFRHSSFLPFTIPHCTSKDTS 400 
gi|4503199|ref|NP_000490.1|      ELDTVIGRSRRPRLSDRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTS 395 
                                 ***  **:.* * ****::** :*:**** ******:******.*::*** 
 
tr|Q6TH23|Q6TH23_DANRE           LNGYFIPKDTCVFVNQWQVNHDPELWKDPSSFIPDRFLTADGTELNKLEG 450 
gi|4503199|ref|NP_000490.1|      LKGFYIPKGRCVFVNQWQINHDQKLWVNPSEFLPERFLTPDG-AIDKVLS 444 
                                 *:*::***. ********:*** :** :**.*:*:****.**  ::*: . 
 
tr|Q6TH23|Q6TH23_DANRE           EKVLVFGLGKRRCIGESIGRAEVFLFLAILLQRLKFTGMPGEMLDMTPEY 500 
gi|4503199|ref|NP_000490.1|      EKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEFSVPLGVKVDMTPIY 494 
                                 ***::**:***:****:*.* ************::*:   *  :**** * 
 
tr|Q6TH23|Q6TH23_DANRE           GLTMKHKRCLLRVTPQPVF 519 
gi|4503199|ref|NP_000490.1|      GLTMKHACCEHFQMQLRS- 512 
                                 ******  *           
 
Figure A1:  The allignment of the predicted amino acid sequences for 
CYP1A (Danio rerio, Q6TH23_DANRE) and CYP1A1 (Homo sapiens, 
NP_000490.1) using the ClustalW software availible at 
http://www.ebi.ac.uk/Tools/clustalw2/index.html (accessed December 
2009).  Identical residues indicated by *, conserved substitutions (based 
upon the chemical properties of the amino acids – e.g. acidic, basic or 
hydrophobic) indicated by :, and semi-conserved substitutions indicated 
by .. 
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tr|Q9IBG8|Q9IBG8_DANRE           MALENILLHLNSKVWTDAGTILLLFILFLLVSVKLRNRNKPTKTFLLGPT 50 
gi|7949031|ref|NP_000758.1|      MELS-VLLFLA----------LLTGLLLLLVQRHPNTHDR----LPPGPR 35 
                                 * *. :**.*           **  :*:***. : ..:::    :  **  
 
tr|Q9IBG8|Q9IBG8_DANRE           PLPFIGNVFNLDTSQPHICLTKMSDHYGNIFSLRLGSLNTVVVNTYSMVK 100 
gi|7949031|ref|NP_000758.1|      PLPLLGNLLQMDRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCGVEAIR 85 
                                 ***::**::::*      .: :: ::**::*:::**.  .*::   . :: 
 
tr|Q9IBG8|Q9IBG8_DANRE           KVLNDQGNSFMYRPSNDITERILSKCQGLTFNNGYSWKQHRRFTLSTLKF 150 
gi|7949031|ref|NP_000758.1|      EALVDKAEAFSGRGKIAMVDPFF-RGYGVIFANGNRWKVLRRFSVTTMRD 134 
                                 :.* *:.::*  * .  :.: :: :  *: * **  **  ***:::*::  
 
tr|Q9IBG8|Q9IBG8_DANRE           FGVGKRSLEFIIMEEYKFLHQSILDTNGLPFNPHYIINNGVSNIICSMVF 200 
gi|7949031|ref|NP_000758.1|      FGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIICSIVF 184 
                                 **:****:*  * ** : * :.: .::*  ::* ::::. .:*****:** 
 
tr|Q9IBG8|Q9IBG8_DANRE           GRRFEYTDQRFLNMLSLISKALKLQTSVFIQLYAAFPRLMDLLPGPHKEL 250 
gi|7949031|ref|NP_000758.1|      GKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQV 234 
                                 *:**.* **.**:**.*: :::.* :*** **:  *. ::. :**.*::: 
 
tr|Q9IBG8|Q9IBG8_DANRE           FSCFHQVRAFIKEEVDKHRADWDPSSPRDFIDCYLTEIEKMKDDLEAGFH 300 
gi|7949031|ref|NP_000758.1|      YKNLQEINAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFS 284 
                                 :. ::::.*:* ..*:***   ***:*:*:** ** .:** *.: .: *  
 
tr|Q9IBG8|Q9IBG8_DANRE           DEGLQYAVLDLFVAGTETTSTTLLWAFVYMMKY-QKSKKVQAEIDKVVGR 349 
gi|7949031|ref|NP_000758.1|      HQNLNLNTLSLFFAGTETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGP 334 
                                 .:.*:  .*.**.********** :.*: *:** : :::*  **::*:*  
 
tr|Q9IBG8|Q9IBG8_DANRE           YRRPSMDDRPCMPYTDAVIHEIQRMGNVVPLSVPRMTNEDTLLEGLFHSL 399 
gi|7949031|ref|NP_000758.1|      HRPPELHDRAKMPYTEAVIYEIQRFSDLLPMGVPHIVTQHTSFRG-YIIP 383 
                                 :* *.:.**. ****:***:****:.:::*:.**::..:.* :.* :    
 
tr|Q9IBG8|Q9IBG8_DANRE           RVLQIIPNLTSVLFDQTKWKTQHSFDPQNFLNAQGKLKSLKLLSPFSLGK 449 
gi|7949031|ref|NP_000758.1|      KDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGALKKTEAFIPFSLGK 433 
                                 :  :::  *::.*.*   ::. .:*:*::**:*:* **. : : ****** 
 
tr|Q9IBG8|Q9IBG8_DANRE           RSCPGESLARMELFLFFTSFLQSFSLSAP--DETQTSLDFKCGMTLSPKP 497 
gi|7949031|ref|NP_000758.1|      RICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKIPPT 483 
                                 * * **.:** *******::**.**:::*   *       :**:   * . 
 
tr|Q9IBG8|Q9IBG8_DANRE           FKICFTPR 505 
gi|7949031|ref|NP_000758.1|      YQIRFLPR 491 
                                 ::* * ** 
 
 
Figure A2:  The allignment of the predicted amino acid sequences for 
CYP2J26 (Danio rerio, Q9IBG8_DANRE) and CYP2B6 (Homo sapiens, 
NP_000758.1) using the ClustalW software availible at 
http://www.ebi.ac.uk/Tools/clustalw2/index.html (accessed December 
2009).  Identical residues indicated by *, conserved substitutions (based 
upon the chemical properties of the amino acids – e.g. acidic, basic or 
hydrophobic) indicated by :, and semi-conserved substitutions indicated 
by .. 
 
Substrate Human Genes Rate References Rate References Rate References Rate References Rate References Notes
7-Ethoxyresorufin CYP1A, CYP1B1, 28.2 Chan et al 2009 100 ± 23 Sun et al 2006 100 ± 50 Ueng et al 2002 YES Billard et al 2006 43.8 Sadar and Andersson 2001 zebrafish larvae assessed using fluorescence microscopy
(O-deethylation)  CYP1D1 99 ± 10 Sun et al 2006 66.96 ± 1.55 Krajka-Kuźniak and Baer-Dubowska 2003 13 Maurice et al 1991 < 20 (adult liver) Troxel et al 1997 168.6 ± 58.8 Moutou et al 1998
280 ± 80 Ueng et al 2002 664 ± 74 (pmol/min/nmol P450) Chung et al 2004 3130 ± 270 Page and Davies 2002 Zebrafish CYP1A over-expressed in yeast
74 ± 9 Madra et al 1996 < 1 at (3 and 4 dpf) Mattingly and Tuscano 2001 Zebrafish larval homogenates (< 5 dpf)
0.0008 - 0.0016 pmol/min/larvae Noury et al 2006 Live zebrafish larvae
7-Ethoxycoumarin CYP2-family 704 Chan et al 2009 11 Greenlee and Poland 1978 520 Maurice et al 1991 19.9 Sadar and Andersson 2001
(O-deethylation) 24 Greenlee and Poland 1978 42 ± 2.3 González et al 2009
Methoxyresorufin CYP1A2 21.5 Chan et al 2009 130 ± 13 Sun et al 2006 70 ± 20 Ueng et al 2002 120 (juvenile) Arukwe et al 2008 1190 ± 250 Page and Davies 2002
(O-demethylation) 41 ± 14 Sun et al 2006 145.57 ± 3.87 Krajka-Kuźniak and Baer-Dubowska 2003
1420 ± 170 Ueng et al 2002
Pentoxyresorufin CYP2B1 20.3 Chan et al 2009 13.6 ± 2.2 Sun et al 2006 50 (juvenile) Arukwe et al 2008 1720 ± 250 Page and Davies 2002
(O-deethylation) 21 ± 10 Sun et al 2006 36.38 ± 1.99 Krajka-Kuźniak and Baer-Dubowska 2003
7 ± 1 Madra et al 1996
Benzyloxyresorufin
CYP1A1, CYP2B1, 
37.9 ± 6.8 Sun et al 2006 80 ± 17 Sun et al 2006 25 (juvenile) Arukwe et al 2008 7.3 ± 2.2 Moutou et al 1998
(O-deethylation) CYP3A1 30 ± 3 Madra et al 1996 1940 ± 50 Page and Davies 2002
Gender differences observed for rat and mouse (Miura et al 1989)
Testosterone CYP3A4 YES Miura et al 1989 YES Miura et al 1989 YES Miura et al 1989 YES Reschly et al 2008 Zebrafish  liver cell line
(6β-hydroxylation) 21.2 ± 5.6 Fayer et al 2002 Primary human hepatocytes (Fayer et al 2002)
Aflatoxin B1 CYP1A2, CYP3A 20 Buening et al 1981 71 ± 5 (pmol/min/nmol P450) Wang-Buhler et al 2005 185 ± 2 (pmol/min/nmol P450) Wang-Buhler et al 2005 Zebrafish CYP2K6 and rainbow trout CYP2K1 over-expressed in insect cells
Troxel et al 1997 66.6 ± 7.1 Troxel et al 1997 Aflatoxicol and glucuronide metabolites excreted by adult zebrafish (HPLC) and human microsomes
11.7 ± 1.4 (adult) Troxel et al 1997 Liver homogenates measuring aflatoxin B1-8,9-epoxide in zebrafish and rainbow trout
Rainbow troutMouseRat Human Zebrafish
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Benzo-[a]-pyrene CYP1A, CYP2C, 580 ± 140 Krajka-Kuźniak and Baer-Dubowska 2003 120 ± 40 Ueng et al 2002 1160 ± 113 (pmol/min/nmol P450) Chung et al 2004 Zebrafish CYP1A over-expressed in yeast
(hydroxylation)  CYP3A4
A multi-species comparison of the metabolism of model CYP indicator reactions and xenobiotic compounds assessed in zebrafish adult and larvae, compared with rat, mouse, human and rainbow trout.  Activities are expressed as pmol product/minute/mg of 
tissue unless otherwise stated. 
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Publications 
Research Papers 
Jones H, Panter G, Hutchinson T, Chipman JK (2010).  Oxidative and conjugative metabolism in zebrafish larvae in vivo.  Zebrafish, in 
press. 
Conference attendance – poster presentations 
British Toxicology Society annual conference (April 2008, Surrey, UK) – Cytochrome P450s and glucuronosyl transferase in zebrafish larvae. 
British Toxicology Society annual conference (March 2009, Warwick, UK) – Assessment of non-steroidal anti-iflammatory drug (NSAID) 
metabolism by zebrafish larvae using liquid chromatography-mass spectrometry (LC-MS). 
Pollution Responses In Marine Organisms (May 2009, Bordeaux, France) - Assessment of non-steroidal anti-iflammatory drug (NSAID) 
metabolism by zebrafish larvae using liquid chromatography-mass spectrometry (LC-MS). 
 
Conference attendance – platform presentations 
Society of Environmental Toxicology and Chemistry UK meeting (September 2008, Reading, UK) – Expression and activities of xenobiotic 
metabolising enzymes in zebrafish larvae: paracetamol metabolism as an example of an environmentally relevant pharmaceutical. 
Northern Zebrafish Network Meeting (May 2009, Manchester, UK) – Assessment of ibuprofen metabolism by zebrafish larvae using liquid 
chromatography-mass spectrometry 
 
Invited presentations 
International Society for the Study of Xenobiotics (ISSX) European meeting (May 2009, Lisbon, Portugal), Short course 4: zebrafish for 
metabolic and toxicity studies – Xenobiotic metabolism and excretion in zebrafish. 
